Cover Page
Cover Page - shares | 9 Months Ended | |
Mar. 28, 2021 | Apr. 26, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 28, 2021 | |
Document Transition Report | false | |
Entity File Number | 0-12933 | |
Entity Registrant Name | LAM RESEARCH CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-2634797 | |
Entity Address, Address Line One | 4650 Cushing Parkway, | |
Entity Address, City or Town | Fremont, | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94538 | |
City Area Code | 510 | |
Local Phone Number | 572-0200 | |
Title of 12(b) Security | Common Stock, Par Value $0.001 Per Share | |
Trading Symbol | LRCX | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 142,619,346 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0000707549 | |
Current Fiscal Year End Date | --06-27 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Income Statement [Abstract] | ||||
Revenue | $ 3,847,654 | $ 2,503,625 | $ 10,480,971 | $ 7,252,872 |
Cost of goods sold | 2,067,523 | 1,336,618 | 5,590,866 | 3,924,511 |
Gross margin | 1,780,131 | 1,167,007 | 4,890,105 | 3,328,361 |
Research and development | 381,120 | 307,914 | 1,111,659 | 913,602 |
Selling, general, and administrative | 203,703 | 164,979 | 612,350 | 496,679 |
Total operating expenses | 584,823 | 472,893 | 1,724,009 | 1,410,281 |
Operating income | 1,195,308 | 694,114 | 3,166,096 | 1,918,080 |
Other expense, net | (35,320) | (64,619) | (104,053) | (91,271) |
Income before income taxes | 1,159,988 | 629,495 | 3,062,043 | 1,826,809 |
Income tax expense | (88,867) | (54,714) | (298,242) | (271,729) |
Net income | $ 1,071,121 | $ 574,781 | $ 2,763,801 | $ 1,555,080 |
Net income per share: | ||||
Basic (in dollars per share) | $ 7.51 | $ 3.96 | $ 19.20 | $ 10.75 |
Diluted (in dollars per share) | $ 7.41 | $ 3.88 | $ 18.94 | $ 10.39 |
Number of shares used in per share calculations: | ||||
Basic (in shares) | 142,676 | 145,301 | 143,925 | 144,654 |
Diluted (in shares) | 144,609 | 148,165 | 145,923 | 149,648 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 1,071,121 | $ 574,781 | $ 2,763,801 | $ 1,555,080 |
Other comprehensive income (loss), net of tax: | ||||
Foreign currency translation adjustment | (13,701) | (18,225) | 20,231 | (19,412) |
Cash flow hedges: | ||||
Net unrealized gains (losses) during the period | 8,024 | (29,456) | 12,546 | (26,068) |
Net (gains) losses reclassified into net income | (207) | (924) | 843 | 1,810 |
Net change | 7,817 | (30,380) | 13,389 | (24,258) |
Available-for-sale investments: | ||||
Net unrealized losses during the period | (1,623) | (4,129) | (3,667) | (6,842) |
Net losses reclassified into net income | 162 | 27 | 727 | 1,010 |
Net change | (1,461) | (4,102) | (2,940) | (5,832) |
Defined benefit plans, net change in unrealized component | 174 | 278 | 234 | 856 |
Other comprehensive (loss) income, net of tax | (7,171) | (52,429) | 30,914 | (48,646) |
Comprehensive income | $ 1,063,950 | $ 522,352 | $ 2,794,715 | $ 1,506,434 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 | [1] |
ASSETS | |||
Cash and cash equivalents | $ 3,673,366 | $ 4,915,172 | |
Investments | 2,116,101 | 1,795,080 | |
Accounts receivable, less allowance of $5,191 as of March 28, 2021, and $5,465 as of June 28, 2020 | 2,809,068 | 2,097,099 | |
Inventories | 2,552,032 | 1,900,024 | |
Prepaid expenses and other current assets | 171,703 | 146,160 | |
Total current assets | 11,322,270 | 10,853,535 | |
Property and equipment, net | 1,279,836 | 1,071,499 | |
Restricted cash and investments | 253,460 | 253,911 | |
Goodwill | 1,489,990 | 1,484,436 | |
Intangible assets, net | 143,264 | 168,532 | |
Other assets | 796,093 | 727,134 | |
Total assets | 15,284,913 | 14,559,047 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||
Trade accounts payable | 760,942 | 592,387 | |
Accrued expenses and other current liabilities | 1,292,174 | 1,272,655 | |
Deferred profit | 733,783 | 457,523 | |
Current portion of long-term debt and finance lease obligations | 825,434 | 839,877 | |
Total current liabilities | 3,612,333 | 3,162,442 | |
Long-term debt and finance lease obligations, less current portion | 4,991,613 | 4,970,848 | |
Income taxes payable | 924,629 | 909,709 | |
Other long-term liabilities | 381,505 | 332,559 | |
Total liabilities | 9,910,080 | 9,375,558 | |
Commitments and contingencies | |||
Temporary equity, convertible notes | 3,217 | 10,995 | |
Stockholders’ equity: | |||
Preferred stock, at par value of $0.001 per share; authorized, 5,000 shares, none outstanding | 0 | 0 | |
Common stock, at par value of $0.001 per share; authorized, 400,000 shares as of March 28, 2021 and June 28, 2020; issued and outstanding, 142,607 shares at March 28, 2021, and 145,331 shares at June 28, 2020 | 143 | 145 | |
Additional paid-in capital | 6,922,023 | 6,695,858 | |
Treasury stock, at cost; 150,111 shares at March 28, 2021, and 145,432 shares at June 28, 2020 | (15,212,934) | (12,949,889) | |
Accumulated other comprehensive loss | (63,297) | (94,211) | |
Retained earnings | 13,725,681 | 11,520,591 | |
Total stockholders’ equity | 5,371,616 | 5,172,494 | |
Total liabilities and stockholders’ equity | $ 15,284,913 | $ 14,559,047 | |
[1] | Derived from audited financial statements |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 |
Statement of Financial Position [Abstract] | ||
Accounts receivable, allowance for doubtful accounts | $ 5,191 | $ 5,465 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 400,000,000 | 400,000,000 |
Common stock, shares issued (in shares) | 142,607,000 | 145,331,000 |
Common stock, shares outstanding (in shares) | 142,607,000 | 145,331,000 |
Treasury stock, shares (in shares) | 150,111,000 | 145,432,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 28, 2021 | Mar. 29, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ 2,763,801 | $ 1,555,080 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 228,754 | 197,442 |
Deferred income taxes | (5,448) | 74,516 |
Equity-based compensation expense | 163,843 | 136,044 |
Amortization of note discounts and issuance costs | 4,251 | 4,611 |
Other, net | 6,143 | 11,510 |
Changes in operating assets and liabilities | (1,009,116) | (665,800) |
Net cash provided by operating activities | 2,152,228 | 1,313,403 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Capital expenditures and intangible assets | (244,474) | (152,685) |
Purchases of available-for-sale securities | (3,242,741) | (1,889,823) |
Maturities of available-for-sales securities | 1,951,037 | 1,163,555 |
Sales of available-for-sale securities | 956,261 | 1,065,618 |
Other, net | (35,873) | (540) |
Net cash (used for) provided by investing activities | (615,790) | 186,125 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Principal payments on debt | (40,014) | (664,589) |
Proceeds from borrowings on revolving credit facility | 0 | 1,250,000 |
Treasury stock purchases | (2,266,449) | (1,328,632) |
Dividends paid | (541,607) | (489,099) |
Reissuance of treasury stock related to employee stock purchase plan | 41,434 | 38,447 |
Proceeds from issuance of common stock | 23,272 | 6,215 |
Other, net | (1,844) | 328 |
Net cash used for financing activities | (2,785,208) | (1,187,330) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 6,513 | (9,853) |
Net (decrease) increase in cash, cash equivalents, and restricted cash | (1,242,257) | 302,345 |
Cash, cash equivalents, and restricted cash at beginning of period | 5,169,083 | 3,913,396 |
Cash, cash equivalents, and restricted cash at end of period | 3,926,826 | 4,215,741 |
Schedule of non-cash transactions: | ||
Accrued payables for stock repurchases | 5,855 | 295 |
Accrued payables for capital expenditures | 80,215 | 29,690 |
Transfers of inventory to property and equipment, net | 59,882 | 34,155 |
Reconciliation of cash, cash equivalents, and restricted cash | ||
Total cash, cash equivalents, and restricted cash | $ 3,926,826 | $ 4,215,741 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Total | Cumulative effect adjustment | Common Stock | Additional Paid-in Capital | Treasury Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Retained EarningsCumulative effect adjustment | |||
Beginning balance (in shares) at Jun. 30, 2019 | 144,433 | ||||||||||
Beginning balance at Jun. 30, 2019 | $ 4,673,865 | $ 3,018 | $ 144 | $ 6,409,405 | $ (11,602,573) | $ (64,030) | $ 9,930,919 | $ 3,018 | |||
Increase (Decrease) in Stockholders' Equity | |||||||||||
Issuance of common stock (in shares) | 1,230 | ||||||||||
Issuance of common stock | 6,215 | $ 1 | 6,214 | ||||||||
Purchase of treasury stock (in shares) | (5,215) | ||||||||||
Purchase of treasury stock | (1,328,898) | $ (4) | (1,328,894) | ||||||||
Reissuance of treasury stock (in shares) | 296 | ||||||||||
Reissuance of treasury stock | 38,447 | 25,710 | 12,737 | ||||||||
Equity-based compensation expense | 136,044 | 136,044 | |||||||||
Effect of conversion of convertible notes (in shares) | 4,412 | ||||||||||
Effect of conversion of convertible notes | (37,440) | $ 4 | (37,444) | ||||||||
Reclassification from temporary to permanent equity | 37,893 | 37,893 | |||||||||
Net income | 1,555,080 | 1,555,080 | |||||||||
Other comprehensive income (loss) | (48,646) | (48,646) | |||||||||
Cash dividends declared | (497,971) | (497,971) | |||||||||
Ending balance (in shares) at Mar. 29, 2020 | 145,156 | ||||||||||
Ending balance at Mar. 29, 2020 | 4,537,607 | $ 145 | 6,577,822 | (12,918,730) | (112,676) | 10,991,046 | |||||
Beginning balance (in shares) at Dec. 29, 2019 | 142,462 | ||||||||||
Beginning balance at Dec. 29, 2019 | 4,379,429 | $ 142 | 6,528,821 | (12,673,292) | (60,247) | 10,584,005 | |||||
Increase (Decrease) in Stockholders' Equity | |||||||||||
Issuance of common stock (in shares) | 1,047 | ||||||||||
Issuance of common stock | 1,714 | $ 1 | 1,713 | ||||||||
Purchase of treasury stock (in shares) | (1,576) | ||||||||||
Purchase of treasury stock | (245,439) | $ (1) | (245,438) | ||||||||
Equity-based compensation expense | 47,414 | 47,414 | |||||||||
Effect of conversion of convertible notes (in shares) | 3,223 | ||||||||||
Effect of conversion of convertible notes | (26,881) | $ 3 | (26,884) | ||||||||
Reclassification from temporary to permanent equity | 26,758 | 26,758 | |||||||||
Net income | 574,781 | 574,781 | |||||||||
Other comprehensive income (loss) | (52,429) | (52,429) | |||||||||
Cash dividends declared | (167,740) | (167,740) | |||||||||
Ending balance (in shares) at Mar. 29, 2020 | 145,156 | ||||||||||
Ending balance at Mar. 29, 2020 | 4,537,607 | $ 145 | 6,577,822 | (12,918,730) | (112,676) | 10,991,046 | |||||
Beginning balance (in shares) at Jun. 28, 2020 | 145,331 | ||||||||||
Beginning balance at Jun. 28, 2020 | 5,172,494 | [1] | $ 1,157 | [2] | $ 145 | 6,695,858 | (12,949,889) | (94,211) | 11,520,591 | $ 1,157 | [2] |
Increase (Decrease) in Stockholders' Equity | |||||||||||
Issuance of common stock (in shares) | 1,053 | ||||||||||
Issuance of common stock | 23,272 | $ 1 | 23,271 | ||||||||
Purchase of treasury stock (in shares) | (4,887) | ||||||||||
Purchase of treasury stock | (2,272,222) | $ (4) | (2,272,218) | ||||||||
Reissuance of treasury stock (in shares) | 207 | ||||||||||
Reissuance of treasury stock | 41,434 | 32,261 | 9,173 | ||||||||
Equity-based compensation expense | 163,843 | 163,843 | |||||||||
Effect of conversion of convertible notes (in shares) | 903 | ||||||||||
Effect of conversion of convertible notes | (987) | $ 1 | (988) | ||||||||
Reclassification from temporary to permanent equity | 7,778 | 7,778 | |||||||||
Net income | 2,763,801 | 2,763,801 | |||||||||
Other comprehensive income (loss) | 30,914 | 30,914 | |||||||||
Cash dividends declared | (559,868) | (559,868) | |||||||||
Ending balance (in shares) at Mar. 28, 2021 | 142,607 | ||||||||||
Ending balance at Mar. 28, 2021 | 5,371,616 | $ 143 | 6,922,023 | (15,212,934) | (63,297) | 13,725,681 | |||||
Beginning balance (in shares) at Dec. 27, 2020 | 143,205 | ||||||||||
Beginning balance at Dec. 27, 2020 | 5,503,033 | $ 143 | 6,854,681 | (14,135,555) | (56,126) | 12,839,890 | |||||
Increase (Decrease) in Stockholders' Equity | |||||||||||
Issuance of common stock (in shares) | 848 | ||||||||||
Issuance of common stock | 9,626 | $ 1 | 9,625 | ||||||||
Purchase of treasury stock (in shares) | (1,731) | ||||||||||
Purchase of treasury stock | (1,077,380) | $ (1) | (1,077,379) | ||||||||
Equity-based compensation expense | 55,746 | 55,746 | |||||||||
Effect of conversion of convertible notes (in shares) | 285 | ||||||||||
Effect of conversion of convertible notes | (327) | (327) | |||||||||
Reclassification from temporary to permanent equity | 2,298 | 2,298 | |||||||||
Net income | 1,071,121 | 1,071,121 | |||||||||
Other comprehensive income (loss) | (7,171) | (7,171) | |||||||||
Cash dividends declared | (185,330) | (185,330) | |||||||||
Ending balance (in shares) at Mar. 28, 2021 | 142,607 | ||||||||||
Ending balance at Mar. 28, 2021 | $ 5,371,616 | $ 143 | $ 6,922,023 | $ (15,212,934) | $ (63,297) | $ 13,725,681 | |||||
[1] | Derived from audited financial statements | ||||||||||
[2] | (1) Refer to Note 2 - Recent Accounting Pronouncements for more information regarding this Financial Accounting Standards Board (FASB) Accounting Standard Updates. |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Mar. 28, 2021 | Jun. 28, 2020 | [1] | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | Jun. 30, 2019 | |
Statement of Stockholders' Equity [Abstract] | |||||||
Dividends declared per share (in dollars per share) | $ 1.30 | $ 1.15 | $ 3.90 | $ 3.45 | |||
Accounting Standards Update | us-gaap:AccountingStandardsUpdate201818Member | us-gaap:AccountingStandardsUpdate201602Member | |||||
[1] | (1) Refer to Note 2 - Recent Accounting Pronouncements for more information regarding this Financial Accounting Standards Board (FASB) Accounting Standard Updates. |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 9 Months Ended |
Mar. 28, 2021 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION | BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of Lam Research Corporation (“Lam Research” or the “Company”) for the fiscal year ended June 28, 2020, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended June 28, 2020 (the “2020 Form 10-K”). The Company’s reports on Form 10-K, Form 10-Q and Form 8-K are available online at the Securities and Exchange Commission website on the Internet. The address of that site is www.sec.gov . The Company also posts its reports on Form 10-K, Form 10-Q and Form 8-K on its corporate website at http://investor.lamresearch.com . The content on any website referred to in this Form 10-Q is not a part of or incorporated by reference in this Form 10-Q unless expressly noted. The condensed consolidated financial statements include the accounts of Lam Research and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year will end June 27, 2021 and includes 52 weeks. The quarters ended March 28, 2021 (the “March 2021 quarter”) and March 29, 2020 (the “March 2020 quarter”) included 13 weeks. |
RECENT ACCOUNTING PRONOUNCEMENT
RECENT ACCOUNTING PRONOUNCEMENTS | 9 Months Ended |
Mar. 28, 2021 | |
Accounting Changes and Error Corrections [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) released Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326).” The amendment revises the impairment model to utilize an expected loss methodology in place of the previously used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including but not limited to, available for sale debt securities and accounts receivable. The FASB issued a subsequent amendment to the initial guidance in April 2019 and November 2019 within ASU 2019-04 and ASU 2019-11, respectively. The adoption of these standards in the first quarter of fiscal year 2021 did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements (Topic 808).” The amendment clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a good or service that is a distinct unit of account. The amendment also precludes entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The adoption of this standard in the first quarter of fiscal year 2021 did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU provides temporary optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, “ Reference Rate Reform (Topic 848),” which permits entities to apply optional expedients in Topic 848 to derivative instruments modified because of discounting transition resulting from reference rate reform. ASU 2020-04 became effective upon issuance and may be applied prospectively to contract modifications made on or before December 31, 2022. ASU 2021-01 became effective upon issuance and may be applied on a full retrospective basis as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively for contract modifications made on or before December 31, 2022. The Company has not yet applied the relief afforded by these standard amendments and is currently assessing contracts that will require modification due to reference rate reform to which these standard amendments may be applied. |
REVENUE
REVENUE | 9 Months Ended |
Mar. 28, 2021 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE | REVENUE Deferred Revenue Revenue of $69.1 million and $427.2 million included in deferred revenue as of June 28, 2020 was recognized during the three and nine months ended March 28, 2021. The following table summarizes the transaction price for contracts that have not yet been recognized as revenue as of March 28, 2021 and when the Company expects to recognize the amounts as revenue: Less than 1 Year 1-3 Years More than 3 Years Total (In thousands) Deferred revenue $ 661,240 $ 156,040 (1) $ — $ 817,280 (1) This amount is reported in Deferred profit on the Company's Condensed Consolidated Balance Sheets as the customers can demand the liability to be performed at any time. Disaggregation of Revenue The Company operates in one reportable business segment: manufacturing and servicing of wafer processing semiconductor manufacturing equipment. The Company’s material operating segments qualify for aggregation due to their customer base and similarities in economic characteristics, nature of products and services, and processes for procurement, manufacturing, and distribution. The Company operates in seven geographic regions: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. For geographical reporting, revenue is attributed to the geographic location in which the customers’ facilities are located. The Company serves three primary markets: memory, foundry, and logic/integrated device manufacturing. The following table presents the Company’s revenues disaggregated between system and its customer support-related revenue: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (In thousands) System revenue $ 2,545,306 $ 1,647,560 $ 7,000,968 $ 4,759,881 Customer support-related revenue and other 1,302,348 856,065 3,480,003 2,492,991 $ 3,847,654 $ 2,503,625 $ 10,480,971 $ 7,252,872 System revenue includes sales of new leading-edge equipment in deposition, etch and clean markets. Customer support-related revenue includes sales of customer service, spares, upgrades, and non-leading-edge equipment from the Company’s Reliant product line. The following table presents the Company’s revenues disaggregated by geographic region: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (In thousands) China $ 1,217,427 $ 792,412 $ 3,600,281 $ 2,142,366 Korea 1,195,711 589,072 2,664,493 1,503,733 Taiwan 545,719 515,485 1,576,109 1,587,848 Japan 262,913 239,751 999,462 721,664 Southeast Asia 260,360 62,800 829,157 460,723 United States 184,887 215,015 460,271 622,399 Europe 180,637 89,090 351,198 214,139 $ 3,847,654 $ 2,503,625 $ 10,480,971 $ 7,252,872 The following table presents the percentages of leading- and non-leading-edge equipment and upgrade revenue to each of the primary markets the Company serves: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, Memory 62 % 56 % 62 % 57 % Foundry 31 % 31 % 31 % 31 % Logic/integrated device manufacturing 7 % 13 % 7 % 12 % |
EQUITY-BASED COMPENSATION PLANS
EQUITY-BASED COMPENSATION PLANS | 9 Months Ended |
Mar. 28, 2021 | |
Share-based Payment Arrangement [Abstract] | |
EQUITY-BASED COMPENSATION PLANS | EQUITY-BASED COMPENSATION PLANS The Lam Research Corporation 2015 Stock Incentive Plan, as amended (the “2015 Plan”), provides for the grant of non-qualified equity-based awards of the Company’s Common Stock to eligible employees and non-employee directors, including stock options, restricted stock units (“RSUs”), and market-based performance RSUs (“market-based PRSUs”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue a set number of shares of Common Stock at the time of vesting. The Company’s market-based PRSUs contain both a market condition and a service condition. The Company’s option, RSU, and market-based PRSU awards typically vest over a period of three years. The Company also has an employee stock purchase plan that allows employees to purchase its Common Stock at a discount through payroll deductions. The Company recognized the following equity-based compensation expense (including expense related to the employee stock purchase plan) and related income tax benefit in the Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Equity-based compensation expense $ 55,746 $ 47,414 $ 163,843 $ 136,044 Income tax benefit recognized related to equity-based compensation expense $ 44,077 $ 24,457 $ 63,866 $ 38,736 |
OTHER EXPENSE, NET
OTHER EXPENSE, NET | 9 Months Ended |
Mar. 28, 2021 | |
Other Income and Expenses [Abstract] | |
OTHER EXPENSE, NET | OTHER EXPENSE, NET The significant components of other expense, net, are as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Interest income $ 4,209 $ 18,856 $ 15,964 $ 76,094 Interest expense (52,236) (41,580) (156,902) (128,190) Gains (losses) on deferred compensation plan-related assets, net 7,520 (33,828) 44,654 (20,135) Foreign exchange gains (losses), net 541 480 (4,597) (2,336) Other, net 4,646 (8,547) (3,172) (16,704) $ (35,320) $ (64,619) $ (104,053) $ (91,271) |
INCOME TAX EXPENSE
INCOME TAX EXPENSE | 9 Months Ended |
Mar. 28, 2021 | |
Income Tax Disclosure [Abstract] | |
INCOME TAX EXPENSE | INCOME TAX EXPENSE The Company’s provision for income taxes and effective tax rate are as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands, except percentages) Income tax expense $ 88,867 $ 54,714 $ 298,242 $ 271,729 Effective tax rate 7.7 % 8.7 % 9.7 % 14.9 % The difference between the U.S. federal statutory tax rate of 21% and the Company’s effective tax rate for the three and nine months ended March 28, 2021 and the three and nine months ended March 29, 2020 was primarily due to income in lower tax jurisdictions, stock-based compensation excess tax benefits, and a cumulative income tax benefit reversal due to a court ruling in the nine months ended March 29, 2020. The Internal Revenue Service (“IRS”) is examining the Company’s U.S. federal income tax return for the fiscal year ended June 24, 2018. As of March 28, 2021, no significant adjustments have been proposed by the IRS. The Company is unable to make a reasonable estimate as to when cash settlements, if any, with the IRS will occur. The Company is in various stages of examinations in connection with all of its tax audits worldwide, and it is difficult to determine when these examinations will be settled. It is reasonably possible that over the next 12-month period the Company may experience an increase or decrease in its uncertain tax positions as a result of tax examinations or lapses of statutes of limitations. The change in uncertain tax positions as a result of lapses of statutes of limitations may range up to $7.4 million. |
NET INCOME PER SHARE
NET INCOME PER SHARE | 9 Months Ended |
Mar. 28, 2021 | |
Earnings Per Share [Abstract] | |
NET INCOME PER SHARE | NET INCOME PER SHARE Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, restricted stock units, and convertible notes. Refer to Note 12 - Long-term Debt and Other Borrowings for additional information regarding the Company’s convertible notes. The following table reconciles the inputs to the basic and diluted computations for net income per share. Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands, except per share data) Numerator: Net income $ 1,071,121 $ 574,781 $ 2,763,801 $ 1,555,080 Denominator: Basic average shares outstanding 142,676 145,301 143,925 144,654 Effect of potential dilutive securities: Employee stock plans 1,415 1,453 1,273 1,390 Convertible notes 518 1,411 725 3,604 Diluted average shares outstanding 144,609 148,165 145,923 149,648 Net income per share - basic $ 7.51 $ 3.96 $ 19.20 $ 10.75 Net income per share - diluted $ 7.41 $ 3.88 $ 18.94 $ 10.39 For purposes of computing diluted net income per share, weighted-average common shares do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. The following potentially dilutive securities were excluded: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Options and RSUs 120 40 40 13 |
FINANCIAL INSTRUMENTS
FINANCIAL INSTRUMENTS | 9 Months Ended |
Mar. 28, 2021 | |
Fair Value Disclosures [Abstract] | |
FINANCIAL INSTRUMENTS | FINANCIAL INSTRUMENTS The Company maintains an investment portfolio of various holdings, types, and maturities. The Company’s mutual funds, which are related to the Company’s obligations under the deferred compensation plan, are classified as trading securities. Investments classified as trading securities are recorded at fair value based upon quoted market prices. Differences between the cost and fair value of trading securities are recognized as other expense, net in the Condensed Consolidated Statements of Operations. All of the Company’s other investments are classified as available-for-sale and consequently are recorded in the Condensed Consolidated Balance Sheets at fair value with unrealized gains or losses associated with market valuation changes, unrelated to credit losses, reported as a separate component of accumulated other comprehensive income (loss), net of tax; and credit losses, if any, recognized as other expense, net in the Condensed Consolidated Statements of Operations. Fair Value The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability. A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The level of an asset or liability in the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities with sufficient volume and frequency of transactions. Level 2: Valuations based on observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or model-derived valuations techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Valuations based on unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities and based on non-binding, broker-provided price quotes and may not have been corroborated by observable market data. The Company engages with pricing vendors to provide fair values for a majority of its Level 1 and Level 2 investments. The vendors provide either a quoted market price in an active market or use observable inputs without applying significant adjustments in their pricing. Significant observable inputs include interest rates and yield curves observable at commonly quoted intervals, volatility and credit risks. The fair value of derivative contracts is determined using observable market inputs such as the foreign currency rates, forward rate curves, currency volatility and interest rates and considers nonperformance risk of the Company and its counterparties. The Company’s primary financial instruments include its cash, cash equivalents, investments, restricted cash and investments, long-term investments, accounts receivable, accounts payable, long-term debt and leases, and foreign currency related derivative instruments. The estimated fair value of cash, accounts receivable, and accounts payable approximates their carrying value due to the short period of time to their maturities. Refer to Note 12 - Long-Term Debt and Other Borrowings for additional information regarding the fair value of the Company’s senior notes and convertible senior notes. Investments The following tables set forth the Company’s cash, cash equivalents, investments, restricted cash and investments, and other assets measured at fair value on a recurring basis as of March 28, 2021, and June 28, 2020: March 28, 2021 (Reported Within) Cost Unrealized Unrealized Fair Value Cash and Investments Restricted Other (in thousands) Cash $ 753,473 $ — $ — $ 753,473 $ 750,040 $ — $ 3,433 $ — Time deposits 1,349,934 — — 1,349,934 1,099,907 — 250,027 — Level 1: Money market funds 1,638,280 — — 1,638,280 1,638,280 — — — U.S. Treasury and agencies 385,461 209 (13) 385,657 — 385,657 — — Mutual funds 84,377 10,471 (105) 94,743 — — — 94,743 Level 1 Total 2,108,118 10,680 (118) 2,118,680 1,638,280 385,657 — 94,743 Level 2: Government-sponsored enterprises 3,500 12 — 3,512 — 3,512 — — Foreign government bonds 47,099 43 (1) 47,141 — 47,141 — — Corporate notes and bonds 1,844,375 2,569 (633) 1,846,311 185,139 1,661,172 — — Mortgage backed securities — residential 6,279 74 — 6,353 — 6,353 — — Mortgage backed securities — commercial 12,264 33 (31) 12,266 — 12,266 — — Level 2 Total 1,913,517 2,731 (665) 1,915,583 185,139 1,730,444 — — Total $ 6,125,042 $ 13,411 $ (783) $ 6,137,670 $ 3,673,366 $ 2,116,101 $ 253,460 $ 94,743 June 28, 2020 (Reported Within) Cost Unrealized Unrealized Fair Value Cash and Investments Restricted Other (in thousands) Cash $ 977,862 $ — $ — $ 977,862 $ 973,978 $ — $ 3,884 $ — Time deposits 2,244,655 — — 2,244,655 1,994,628 — 250,027 — Level 1: Money market funds 1,709,350 — — 1,709,350 1,709,350 — — — U.S. Treasury and agencies 552,088 373 (9) 552,452 76,992 475,460 — — Mutual funds 68,784 4,571 (928) 72,427 — — — 72,427 Level 1 Total 2,330,222 4,944 (937) 2,334,229 1,786,342 475,460 — 72,427 Level 2: Government-sponsored enterprises 31,442 12 — 31,454 25,999 5,455 — — Foreign government bonds 10,693 28 (5) 10,716 2,540 8,176 — — Corporate notes and bonds 1,405,615 5,344 (302) 1,410,657 131,685 1,278,972 — — Mortgage backed securities — residential 3,142 71 — 3,213 — 3,213 — — Mortgage backed securities — commercial 23,660 144 — 23,804 — 23,804 — — Level 2 Total 1,474,552 5,599 (307) 1,479,844 160,224 1,319,620 — — Total $ 7,027,291 $ 10,543 $ (1,244) $ 7,036,590 $ 4,915,172 $ 1,795,080 $ 253,911 $ 72,427 The Company accounts for its investment portfolio at fair value. Realized gains (losses) for investment sales are specifically identified. Management assesses the fair value of investments in debt securities that are not actively traded through consideration of interest rates and their impact on the present value of the cash flows to be received from the investments. Following the adoption of Accounting Standard Codification Topic 326 (see additional information in Note 2 - Recent Accounting Pronouncements), under Subtopic 326-30, the Company evaluates its investments with fair value less than amortized cost by first considering whether the Company has the intent to sell the security or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. In either such situation, the difference between fair value and amortized cost is recognized as a loss in the income statement. Where such sales are not likely to occur, the Company considers whether a portion of the loss is the result of a credit loss. To the extent such losses are the result of credit losses, those amounts are recognized in the income statement. All other differences between fair value and amortized cost are recognized in other comprehensive income. No such losses were recognized through the income statement during the three and nine months ended March 28, 2021. The Company did not recognize any losses on investments due to other-than-temporary impairments during the three and nine months ended March 29, 2020. Gross realized gains/(losses) from sales of investments were insignificant in the three and nine months ended March 28, 2021 and March 29, 2020. The following is an analysis of the Company’s cash, cash equivalents, investments, and restricted cash and investments in unrealized loss positions; as of March 28, 2021 there are no unrealized loss positions with a duration equal to or greater than twelve months: March 28, 2021 Unrealized Losses Fair Value Gross (in thousands) U.S. Treasury and agencies $ 7,958 $ (13) Municipal notes and bonds 6,468 (105) Foreign government bonds 21,259 (1) Corporate notes and bonds 540,915 (633) Mortgage backed securities — commercial 7,599 (31) $ 584,199 $ (783) The amortized cost and fair value of cash equivalents, investments, and restricted investments with contractual maturities are as follows as of March 28, 2021: Cost Fair (in thousands) Due in one year or less $ 4,270,859 $ 4,271,415 Due after one year through five years 967,417 969,055 Due in more than five years 48,916 48,984 $ 5,287,192 $ 5,289,454 The Company has the ability, if necessary, to liquidate its investments in order to meet the Company’s liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than 12 months from the date of purchase nonetheless are classified as short-term on the accompanying Condensed Consolidated Balance Sheets. Derivative Instruments and Hedging The Company carries derivative financial instruments (“derivatives”) on its Condensed Consolidated Balance Sheets at their fair values. The Company enters into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective of reducing volatility of earnings and cash flows related to foreign currency exchange rate fluctuations. In addition, the Company enters into interest rate swap arrangements to manage interest rate risk. The counterparties to these derivatives are large global financial institutions that the Company believes are creditworthy, and therefore, it does not consider the risk of counterparty nonperformance to be material. Under the master netting agreements with the respective counterparties to the Company’s derivative contracts, subject to applicable requirements, the Company is allowed to net settle transactions of the same currency with a single net amount payable by one party to the other. However, the Company has elected to present the derivative assets and derivative liabilities on a gross basis on its balance sheet. As of March 28, 2021 and June 28, 2020, the potential effect of rights of offset associated with the above foreign exchange and interest rate contracts would be immaterial to the Condensed Consolidated Balance Sheets. Cash Flow Hedges The Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations on non-U.S. dollar transactions or cash flows. The Company’s policy is to mitigate the foreign exchange risk arising from the fluctuations in the value of these non-U.S. dollar denominated transactions or cash flows through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that generally expire within 12 months and no later than 24 months. These hedge contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive income (loss) and subsequently recognized in revenue/expense in the same period the hedged items affect earnings. In addition, the Company has entered into interest rate swap agreements to hedge against the variability of cash flows due to changes in certain benchmark interest rates on fixed rate debt. These instruments are designated as cash flow hedges at inception and are settled in conjunction with the issuance of debt. The effective portion of the contracts’ gains or losses is included in accumulated other comprehensive income (loss) and is amortized into income as the hedged item impacts earnings. At inception and at each quarter-end, hedges are tested prospectively and retrospectively for effectiveness using regression analysis. Changes in the fair value of foreign exchange contracts due to changes in time value are included in the assessment of effectiveness. To qualify for hedge accounting, the hedge relationship must meet criteria relating to both the derivative instrument and the hedged item. These criteria include identification of the hedging instrument, the hedged item, the nature of the risk being hedged, and how the hedging instrument’s effectiveness in offsetting the exposure to changes in the hedged item’s fair value or cash flows will be measured. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be tested to demonstrate an expectation of providing highly effective offsetting changes to future cash flows on hedged transactions. When derivative instruments are designated and qualify as effective cash flow hedges, the Company recognizes effective changes in the fair value of the hedging instrument within accumulated other comprehensive income (loss) until the hedged exposure is realized. Consequently, the Company’s results of operations are not subject to fluctuation as a result of changes in the fair value of the derivative instruments. If hedges are not highly effective or if the Company does not believe that the underlying hedged forecasted transactions will occur, the Company may not be able to account for its derivative instruments as cash flow hedges. If this were to occur, future changes in the fair values of the Company’s derivative instruments would be recognized in earnings. Additionally, related amounts previously recorded in other comprehensive income would be reclassified to income immediately. As of March 28, 2021 and June 28, 2020, the fair value of outstanding cash flow hedges was not material. Additionally, as of March 28, 2021, the Company had an immaterial net gain or loss accumulated in other comprehensive income, net of tax, related to foreign exchange cash flow hedges and interest rate contracts which it expects to reclassify from other comprehensive income into earnings over the next 12 months. The following table provides the total notional value of cash flow hedge instruments outstanding as of March 28, 2021: March 28, (In thousands) Buy Contracts $ 328,737 Sell Contracts 352,034 The effect of derivative instruments designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”), was as follows: Three Months Ended Nine Months Ended March 28, 2021 March 28, 2021 Location of Gain (Loss) Recognized in AOCI (Loss) Gain Gain (Loss) Gain Derivatives in Cash Flow Hedging Relationships (in thousands) Foreign Exchange Contracts Revenue $ 15,285 $ (1,323) $ 6,948 $ (3,598) Foreign Exchange Contracts Cost of goods sold (3,473) 1,355 3,429 3,073 Foreign Exchange Contracts Research and Development (1,319) — 950 — Foreign Exchange Contracts Selling, general, and administrative (1,741) 1,326 4,056 2,649 Interest Rate Contracts Other expense, net — (962) — (2,871) $ 8,752 $ 396 $ 15,383 $ (747) Three Months Ended Nine Months Ended March 29, 2020 March 29, 2020 Location of Gain (Loss) Gain (Loss) Gain (Loss) Gain (Loss) Derivatives in Cash Flow Hedging Relationships (in thousands) Foreign Exchange Contracts Revenue $ 6,334 $ 1,279 $ 9,532 $ 773 Foreign Exchange Contracts Cost of goods sold (2,589) (186) (3,656) (2,086) Foreign Exchange Contracts Selling, general, and administrative (1,394) 6 (1,859) (887) Interest Rate Contracts Other expense, net (40,901) (36) (38,507) (106) $ (38,550) $ 1,063 $ (34,490) $ (2,306) Balance Sheet Hedges The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily cash, third-party accounts receivable, accounts payable, and intercompany receivables and payables. These forward contracts are not designated for hedge accounting treatment. Therefore, the change in fair value of these derivatives is recorded as a component of other expense, net and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other expense, net. As of March 28, 2021 and June 28, 2020, the fair value of outstanding balance sheet hedges was not material. The following table provides the total notional value of balance sheet hedge instruments outstanding as of March 28, 2021: March 28, (In thousands) Buy Contracts $ 150,554 Sell Contracts 154,595 The effect of the Company’s balance sheet hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations was as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, Derivatives Not Designated as Hedging Instruments: Location Gain Loss Gain Loss (in thousands) Foreign Exchange Contracts Other expense, net $ 2,992 $ (6,858) $ 6,895 $ (8,788) Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments, restricted cash and investments, trade accounts receivable, and derivative financial instruments used in hedging activities. Cash is placed on deposit at large global financial institutions. Such deposits may be in excess of insured limits. Management believes that the financial institutions that hold the Company’s cash are creditworthy and, accordingly, minimal credit risk exists with respect to these balances. The Company’s overall portfolio of available-for-sale securities must maintain an average minimum rating of “AA-” or “Aa3” as rated by Standard and Poor’s, Fitch Ratings, or Moody’s Investor Services. To ensure diversification and minimize concentration, the Company’s policy limits the amount of credit exposure with any one financial institution or commercial issuer. The Company is exposed to credit losses in the event of nonperformance by counterparties on foreign currency and interest rate hedge contracts that are used to mitigate the effect of exchange rate and interest rate fluctuations, and on contracts related to structured share repurchase arrangements. These counterparties are large global financial institutions, and, to date, no such counterparty has failed to meet its financial obligations to the Company. Credit risk evaluations, including trade references, bank references, and Dun & Bradstreet ratings, are performed on all new customers and the Company monitors its customers’ financial condition and payment performance. In general, the Company does not require collateral on sales. |
INVENTORIES
INVENTORIES | 9 Months Ended |
Mar. 28, 2021 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | INVENTORIES Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. System shipments to customers in Japan, for which title does not transfer until customer acceptance, are classified as finished goods inventory and carried at cost until title transfers. Inventories consist of the following: March 28, June 28, (in thousands) Raw materials $ 1,437,563 $ 1,161,961 Work-in-process 359,402 251,199 Finished goods 755,067 486,864 $ 2,552,032 $ 1,900,024 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS | 9 Months Ended |
Mar. 28, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS Goodwill The balance of goodwill is approximately $1.5 billion as of March 28, 2021 and June 28, 2020. As of March 28, 2021 and June 28, 2020, $61.1 million of the goodwill balance is tax deductible and the remaining balance is not tax deductible due to purchase accounting and applicable foreign law. Intangible Assets The following table provides the Company’s intangible assets, other than goodwill: March 28, 2021 June 28, 2020 Gross Accumulated Net Gross Accumulated Net (in thousands) Customer relationships $ 630,278 $ (569,203) $ 61,075 $ 630,137 $ (532,550) $ 97,587 Existing technology 669,302 (658,632) 10,670 668,992 (654,382) 14,610 Patents and other intangible assets 125,383 (53,864) 71,519 98,342 (42,007) 56,335 Total intangible assets $ 1,424,963 $ (1,281,699) $ 143,264 $ 1,397,471 $ (1,228,939) $ 168,532 The Company recognized $17.9 million and $16.6 million in intangible asset amortization expense during the three months ended March 28, 2021 and March 29, 2020, respectively. The Company recognized $52.3 million and $49.3 million in intangible asset amortization expense during the nine months ended March 28, 2021 and March 29, 2020, respectively. The estimated future amortization expense of intangible assets as of March 28, 2021, is reflected in the table below. The table excludes $13.9 million of capitalized costs for internal-use software that have not been placed into service. Fiscal Year Amount (in thousands) 2021 (remaining 3 months) $ 18,019 2022 68,138 2023 22,274 2024 12,089 2025 6,681 Thereafter 2,164 $ 129,365 |
ACCRUED EXPENSES AND OTHER CURR
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | 9 Months Ended |
Mar. 28, 2021 | |
Payables and Accruals [Abstract] | |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: March 28, June 28, (in thousands) Accrued compensation $ 442,188 $ 402,401 Warranty reserves 156,059 117,839 Income and other taxes payable 99,021 215,652 Dividend payable 185,390 167,129 Other 409,516 369,634 $ 1,292,174 $ 1,272,655 |
LONG-TERM DEBT AND OTHER BORROW
LONG-TERM DEBT AND OTHER BORROWINGS | 9 Months Ended |
Mar. 28, 2021 | |
Debt Disclosure [Abstract] | |
LONG-TERM DEBT AND OTHER BORROWINGS | LONG-TERM DEBT AND OTHER BORROWINGS As of March 28, 2021, and June 28, 2020, the Company’s outstanding debt consisted of the following: March 28, 2021 June 28, 2020 Amount Effective Interest Rate Amount Effective Interest Rate Fixed-rate 2.80% Senior Notes Due June 15, 2021 ("2021 Notes") 800,000 2.95 % 800,000 2.95 % Fixed-rate 3.80% Senior Notes Due March 15, 2025 ("2025 Notes") 500,000 3.87 % 500,000 3.87 % Fixed-rate 3.75% Senior Notes Due March 15, 2026 ("2026 Notes") 750,000 3.86 % 750,000 3.86 % Fixed-rate 4.00% Senior Notes Due March 15, 2029 ("2029 Notes") 1,000,000 4.09 % 1,000,000 4.09 % Fixed-rate 1.90% Senior Note Due June 15, 2030 ("2030 Notes") 750,000 2.01 % 750,000 2.01 % Fixed-rate 2.625% Convertible Notes Due May 15, 2041 ("2041 Notes") 17,289 (1) 4.28 % 48,460 (1) 4.28 % Fixed-rate 4.875% Senior Notes Due March 15, 2049 ("2049 Notes") 750,000 4.93 % 750,000 4.93 % Fixed-rate 2.875% Senior Note Due June 15, 2050 ("2050 Notes") 750,000 2.93 % 750,000 2.93 % Fixed-rate 3.125% Senior Note Due June 15, 2060 ("2060 Notes") 500,000 3.18 % 500,000 3.18 % Total debt outstanding, at par 5,817,289 5,848,460 Unamortized discount (42,443) (53,086) Fair value adjustment - interest rate contracts 7,066 (2) 8,405 (2) Unamortized bond issuance costs (7,649) (8,301) Total debt outstanding, at carrying value $ 5,774,263 $ 5,795,478 Reported as: Current portion of long-term debt $ 813,786 $ 836,107 Long-term debt 4,960,477 4,959,371 Total debt outstanding, at carrying value $ 5,774,263 $ 5,795,478 ____________________________ (1) As of the report date, these notes were convertible at the option of the bondholder. This is a result of the following condition being met: the market value of the Company’s Common Stock was greater than 130% of the convertible notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end. As a result, the 2041 Notes were classified in current liabilities and a portion of the equity component, associated with the convertible notes representing the unamortized discount, was classified in temporary equity on the Company’s Condensed Consolidated Balance Sheets. Additionally, on March 26, 2021, the Company issued a notice of redemption to the existing bondholders, with a redemption date of May 21, 2021. (2) This amount represents a cumulative fair value gain for discontinued hedging relationships, net of an immaterial amount of amortization as of the periods presented. Convertible Senior Notes In June 2012, with the acquisition of Novellus Systems, Inc., the Company assumed $700 million in aggregate principal amount of 2.625% Convertible Senior Notes due May 15, 2041. The Company pays cash interest at an annual rate of 2.625%, on a semi-annual basis on May 15 and November 15 of each year. The 2041 Notes also have a contingent interest payment provision that may require the Company to pay additional interest, up to 0.60% per year, based on certain thresholds, beginning with the semi-annual interest payment on May 15, 2021, and upon the occurrence of certain events, as outlined in the indenture governing the 2041 Notes. The Company separately accounts for the liability and equity components of the 2041 Notes. The initial debt components of the 2041 Notes were valued based on the present value of the future cash flows using the Company’s borrowing rate at the date of the issuance or assumption for similar debt instruments without the conversion feature, which equals the effective interest rate on the liability component disclosed in the table above, respectively. The equity component was initially valued equal to the principal value of the notes, less the present value of the future cash flows using the Company’s borrowing rate at the date of the issuance or assumption for similar debt instruments without a conversion feature, which equated to the initial debt discount. During the three months ended March 28, 2021, the Company notified holders of the 2041 Notes of its intention to exercise the redemption option pursuant to Section 6.01 of the underlying indenture. As such, the 2041 Notes outstanding on May 21, 2021 will be redeemed by the Company at a price equal to outstanding principal plus accrued and unpaid interest. Under certain circumstances, the 2041 Notes may be converted into shares of the Company’s Common Stock. The number of shares each debenture is convertible into is based on conversion rates, disclosed in the table below. The principal value of the 2041 Note conversions in the three and nine months ended March 28, 2021, was approximately $9.6 million and $31.2 million, respectively. As a result of the cumulative conversions, as of March 28, 2021, $17.3 million of the 2041 notes remain outstanding. During the three months ended March 28, 2021 and in the subsequent period through April 28, 2021, the Company received notices of conversion for an immaterial principal value of 2041 Notes, which will settle in the three months ending June 27, 2021. Selected additional information regarding the 2041 Notes outstanding as of March 28, 2021, and June 28, 2020, is as follows: March 28, June 28, 2041 Notes 2041 Notes (in thousands, except years, percentages, conversion rate, and conversion price) Carrying amount of permanent equity component, net of tax $ 161,612 $ 161,467 Carrying amount of temporary equity component, net of tax $ 3,217 $ 10,995 Remaining amortization period (years) 20.1 20.9 Fair Value of Notes (Level 2) $ 319,495 Conversion rate (shares of common stock per $1,000 principal amount of notes) 31.8009 Conversion price (per share of common stock) $ 31.45 If-converted value in excess of par value $ 303,924 Estimated share dilution using average quarterly stock price $538.79 per share 518 Senior Notes On May 5, 2020, the company completed a public offering of $750 million aggregate principal amount of the Company’s Senior Notes due June 15, 2030 (the “2030 Notes”), $750 million aggregate principal amount of the Company’s Senior Notes due June 15, 2050 (the “2050 Notes”), and $500 million aggregate principal amount of the Company’s Senior Notes due June 15, 2060 (the “2060 Notes”). The Company pays interest at an annual rate of 1.90%, 2.875%, and 3.125%, on the 2030, 2050, and 2060 Notes, respectively, on a semi-annual basis on June 15 and December 15 of each year. On March 4, 2019, the company completed a public offering of $750 million aggregate principal amount of the Company’s Senior Notes due March 15, 2026 (the “2026 Notes”), $1.0 billion aggregate principal amount of the Company’s Senior Notes due March 15, 2029 (the “2029 Notes”), and $750 million aggregate principal amount of the Company’s Senior Notes due March 15, 2049 (the “2049 Notes”). The Company pays interest at an annual rate of 3.75%, 4.00%, and 4.875%, on the 2026, 2029, and 2049 Notes, respectively, on a semi-annual basis on March 15 and September 15 of each year. On March 12, 2015, the Company completed a public offering of $500 million aggregate principal amount of the Company’s Senior Notes due March 15, 2025 (the “2025 Notes”). The Company pays interest at an annual rate of 3.80% on the 2025 Notes on a semi-annual basis on March 15 and September 15 of each year. On June 7, 2016, the Company completed a public offering of $800 million aggregate principal amount of Senior Notes due June 2021 (the “2021 Notes”). The Company pays interest at an annual rate of 2.80% on the 2021 Notes on a semi-annual basis on June 15 and December 15 of each year. The Company may redeem the 2021, 2025, 2026, 2029, 2030, 2049, 2050, and 2060 Notes (collectively the “Senior Notes”) at a redemption price equal to 100% of the principal amount of such series (“par”), plus a “make whole” premium as described in the indenture in respect to the Senior Notes and accrued and unpaid interest before May 15, 2021 for the 2021 Notes, before December 15, 2024 for the 2025 Notes, before January 15, 2026 for the 2026 Notes, before December 15, 2028 for the 2029 Notes, before March 15, 2030 for the 2030 Notes, before September 15, 2048 for the 2049 Notes, before December 15, 2049 for the 2050 Notes, and before December 15, 2059 for the 2060 Notes. The Company may redeem the Senior Notes at par, plus accrued and unpaid interest at any time on or after May 15, 2021 for the 2021 Notes, on or after December 24, 2024 for the 2025 Notes, on or after January 15, 2026 for the 2026 Notes, on or after December 15, 2028 for the 2029 Notes, on or after March 15, 2030 for the 2030 Notes, on or after September 15, 2048 for the 2049 Notes, on or after December 15, 2049 for the 2050 Notes, and on or after December 15, 2059 for the 2060 Notes. In addition, upon the occurrence of certain events, as described in the indenture, the Company will be required to make an offer to repurchase the Senior Notes at a price equal to 101% of the principal amount of the respective note, plus accrued and unpaid interest. Selected additional information regarding the Senior Notes outstanding as of March 28, 2021, is as follows: Remaining Amortization period Fair Value of Notes (Level 2) (years) (in thousands) 2021 Notes 0.2 $ 802,480 2025 Notes 4.0 $ 550,435 2026 Notes 5.0 $ 835,095 2029 Notes 8.0 $ 1,139,390 2030 Notes 9.2 $ 729,968 2049 Notes 28.0 $ 973,500 2050 Notes 29.2 $ 711,263 2060 Notes 39.2 $ 484,215 Revolving Credit Facility On March 12, 2014, the Company established an unsecured Credit Agreement. This agreement was amended on November 10, 2015 (the “Amended and Restated Credit Agreement”), October 13, 2017 (the “2nd Amendment”), and February 25, 2019 (the “3rd Amendment”). Under the Amended and Restated Credit Agreement (as amended by the 2nd and 3rd Amendment), the Company has a revolving credit facility of $1.25 billion with a syndicate of lenders with an expansion option that will allow the Company, subject to certain requirements, to request an increase in the facility of up to an additional $600.0 million, for a potential total commitment of $1.85 billion. The facility matures on October 13, 2022. Interest on amounts borrowed under the credit facility is, at the Company’s option, based on (1) a base rate, defined as the greatest of (a) prime rate, (b) Federal Funds rate plus 0.5%, or (c) one-month LIBOR plus 1.0%, plus a spread of 0.0% to 0.5%, or (2) LIBOR multiplied by the statutory rate, plus a spread of 0.9% to 1.5%, in each case as the applicable spread is determined based on the rating of the Company’s non-credit enhanced, senior unsecured long-term debt. Principal and any accrued and unpaid interest is due and payable upon maturity. Additionally, the Company will pay the lenders a quarterly commitment fee that varies based on the Company’s credit rating. The Amended and Restated Credit Agreement contains affirmative covenants, negative covenants, financial covenants and events of default. As of March 28, 2021, the Company had no borrowings outstanding under the credit facility and was in compliance with all financial covenants. Commercial Paper Program On November 13, 2017, the Company established a commercial paper program (“the CP Program”) under which the Company may issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate principal amount of $1.25 billion. The net proceeds from the CP Program will be used for general corporate purposes, including repurchases of the Company’s Common Stock from time to time under the Company’s stock repurchase program. Amounts available under the CP Program may be re-borrowed. The CP Program is backstopped by the Company’s Revolving Credit Arrangement. As of March 28, 2021 and June 28, 2020, the Company had no outstanding borrowings under the CP Program. Interest Cost The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the debt discount, issuance costs, and effective portion of interest rate contracts with respect to the Senior Notes, convertible notes, commercial paper, and the revolving credit facility during the three and nine months ended March 28, 2021 and March 29, 2020. Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Contractual interest coupon $ 49,487 $ 40,409 $ 148,573 $ 122,196 Amortization of interest discount 998 953 3,011 3,346 Amortization of issuance costs 414 408 1,238 1,238 Effect of interest rate contracts, net 516 59 1,533 889 Total interest cost recognized $ 51,415 $ 41,829 $ 154,355 $ 127,669 |
LEASES
LEASES | 9 Months Ended |
Mar. 28, 2021 | |
Leases [Abstract] | |
LEASES | LEASES The Company leases certain office spaces, manufacturing and warehouse spaces, equipment, and vehicles. While the majority of the Company’s lease arrangements are operating leases, the Company has certain leases that qualify as finance leases. Selected Leases and Related Guarantees The Company leases the majority of its administrative, research and development and manufacturing facilities, regional sales/service offices, and certain equipment under non-cancelable leases. Certain of the Company’s facility leases for buildings located at its Fremont, California headquarters, Tualatin, Oregon campus, and certain other facility leases provide the Company with options to extend the leases for additional periods or to purchase the facilities. Certain of the Company’s facility leases provide for periodic rent increases based on the general rate of inflation. The Company had leases regarding certain improved properties in Fremont and Livermore, California (the “California Facility Leases”) that were classified as operating leases as of June 28, 2020. On September 21, 2020, the Company renewed these leases for an additional seven-year term, and concluded the modified leases are finance leases, and recognized approximately $31.4 million of property and equipment, net, for the associated right of use assets, and $29.8 million of finance lease obligations ($3.1 million classified in current portion of long-term debt and finance lease obligations and the remainder in long-term debt and finance lease obligations, less current portion). The Company is required to maintain cash collateral in an aggregate of approximately $250.0 million in separate interest-bearing accounts as security for the Company’s obligations. These amounts are recorded with other restricted cash and investments in the Company’s Condensed Consolidated Balance Sheet as of March 28, 2021. During the term of the California Facility Leases and when the terms of the California Facility Leases expire, the property subject to the California Facility Leases may be re-marketed. The Company has guaranteed to the lessor that each property will have a certain minimum residual value. The aggregate maximum guarantee made by the Company under the California Facility Leases is $298.4 million. |
LEASES | LEASES The Company leases certain office spaces, manufacturing and warehouse spaces, equipment, and vehicles. While the majority of the Company’s lease arrangements are operating leases, the Company has certain leases that qualify as finance leases. Selected Leases and Related Guarantees The Company leases the majority of its administrative, research and development and manufacturing facilities, regional sales/service offices, and certain equipment under non-cancelable leases. Certain of the Company’s facility leases for buildings located at its Fremont, California headquarters, Tualatin, Oregon campus, and certain other facility leases provide the Company with options to extend the leases for additional periods or to purchase the facilities. Certain of the Company’s facility leases provide for periodic rent increases based on the general rate of inflation. The Company had leases regarding certain improved properties in Fremont and Livermore, California (the “California Facility Leases”) that were classified as operating leases as of June 28, 2020. On September 21, 2020, the Company renewed these leases for an additional seven-year term, and concluded the modified leases are finance leases, and recognized approximately $31.4 million of property and equipment, net, for the associated right of use assets, and $29.8 million of finance lease obligations ($3.1 million classified in current portion of long-term debt and finance lease obligations and the remainder in long-term debt and finance lease obligations, less current portion). The Company is required to maintain cash collateral in an aggregate of approximately $250.0 million in separate interest-bearing accounts as security for the Company’s obligations. These amounts are recorded with other restricted cash and investments in the Company’s Condensed Consolidated Balance Sheet as of March 28, 2021. During the term of the California Facility Leases and when the terms of the California Facility Leases expire, the property subject to the California Facility Leases may be re-marketed. The Company has guaranteed to the lessor that each property will have a certain minimum residual value. The aggregate maximum guarantee made by the Company under the California Facility Leases is $298.4 million. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Mar. 28, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Refer to Note 13 - Leases for details regarding guarantees surrounding selected leases. Other Guarantees The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into insurance contracts that are intended to limit its exposure to such indemnifications. As of March 28, 2021, the Company had not recorded any liability on its Condensed Consolidated Financial Statements in connection with these indemnifications, as it does not believe that it is probable that any material amounts will be paid under these guarantees. Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe that it is probable that any material amounts will be paid under these guarantees. The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of March 28, 2021, the maximum potential amount of future payments that the Company could be required to make under these arrangements and letters of credit was $73.2 million. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid. In addition, the Company has entered into indemnification agreements with its officers and directors, consistent with its Bylaws and Certificate of Incorporation; and under local law, the Company may be required to provide indemnification to its employees for actions within the scope of their employment. Although the Company maintains insurance contracts that cover some of the potential liability associated with these indemnification agreements, there is no guarantee that all such liabilities will be covered. The Company does not believe, based on historical experience and information currently available, that it is probable that any material amounts will be required to be paid under such indemnification agreements or statutory obligations. Warranties The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements. As of March 28, 2021, warranty reserves totaling $16.4 million were recognized in other long-term liabilities, the remainder were included in accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheets. Changes in the Company’s product warranty reserves were as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Balance at beginning of period $ 153,214 $ 118,193 $ 129,197 $ 127,932 Warranties issued during the period 60,223 44,898 163,869 115,798 Settlements made during the period (45,792) (31,647) (123,462) (98,563) Changes in liability for pre-existing warranties 4,801 (1,252) 2,842 (14,975) Balance at end of period $ 172,446 $ 130,192 $ 172,446 $ 130,192 Legal Proceedings While the Company is not currently a party to any legal proceedings that it believes material, the Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. Based on current information, the Company does not believe that a material loss from known matters is probable and therefore has not recorded an accrual of any material amount for litigation or other contingencies related to existing legal proceedings. |
STOCK REPURCHASE PROGRAM
STOCK REPURCHASE PROGRAM | 9 Months Ended |
Mar. 28, 2021 | |
Equity [Abstract] | |
STOCK REPURCHASE PROGRAM | STOCK REPURCHASE PROGRAMIn November 2020, the Board of Directors authorized the Company to repurchase up to an additional $5.0 billion of Common Stock; this authorization supplements the remaining balances from any prior authorizations. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. This repurchase program has no termination date and may be suspended or discontinued at any time. Repurchases under the repurchase program were as follows during the periods indicated: Period Total Number of Total Cost of Average Price (1) Amount (in thousands, except per share data) Available balance as of June 28, 2020 $ 1,773,427 Quarter ended September 27, 2020 1,344 $ 461,998 $ 343.73 $ 1,311,429 Board authorization, $5 billion increase, November 2020 $ 6,311,429 Quarter ended December 27, 2020 1,789 $ 724,485 $ 404.98 $ 5,586,944 Quarter ended March 28, 2021 1,474 $ 925,099 $ 519.30 $ 4,661,845 (1) Average price paid per share excludes the effect of accelerated share repurchases. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the nine months ended March 28, 2021. In addition to the shares repurchased under the Board-authorized repurchase program shown above, during the three and nine months ended March 28, 2021, the Company acquired 257 thousand shares at a total cost of $152.3 million and 280 thousand shares at a total cost of $160.6 million, respectively, which the Company withheld through net settlements to cover minimum tax withholding obligations upon the vesting of restricted stock unit awards granted under the Company’s equity compensation plans. The shares retained by the Company through these net share settlements are not a part of the Board-authorized repurchase program but instead are authorized under the Company’s equity compensation plan. Accelerated Share Repurchase Agreements On February 11, 2021, the Company entered into an accelerated share repurchase agreement (the “February 2021 ASR") with a financial institution to repurchase a total of $500 million of Common Stock. The Company took an initial delivery of approximately 655 thousand shares, which represented 75% of the prepayment amount divided by the Company’s closing stock price on February 11, 2021. The total number of shares received under the February 2021 ASR will be based upon the average daily volume weighted average price of the Company’s Common Stock during the repurchase period, less an agreed upon discount. Final settlement of the February 2021 ASR will occur no later than June 9, 2021. |
ACCUMULATED OTHER COMPREHENSIVE
ACCUMULATED OTHER COMPREHENSIVE LOSS | 9 Months Ended |
Mar. 28, 2021 | |
Equity [Abstract] | |
ACCUMULATED OTHER COMPREHENSIVE LOSS | ACCUMULATED OTHER COMPREHENSIVE LOSS The components of accumulated other comprehensive loss, net of tax at March 28, 2021, as well as the activity for the nine months ending March 28, 2021, were as follows: Accumulated Foreign Currency Translation Adjustment Accumulated Accumulated Accumulated Total (in thousands) Balance at June 28, 2020 $ (45,811) $ (32,796) $ 4,923 $ (20,527) $ (94,211) Other comprehensive income (loss) before reclassifications 20,231 12,546 (3,667) 234 29,344 Losses reclassified from accumulated other comprehensive loss to net income — 843 (1) 727 (2) — 1,570 Net current-period other comprehensive income (loss) 20,231 13,389 (2,940) 234 30,914 Balance at March 28, 2021 $ (25,580) $ (19,407) $ 1,983 $ (20,293) $ (63,297) (1) Amount of after-tax loss reclassified from AOCI into net income is not material in the aggregate, or to any individual location in our Condensed Consolidated Statements of Operations. (2) Amount of after-tax loss reclassified from accumulated other comprehensive income into net income located in other expense, net. |
BASIS OF PRESENTATION (Policies
BASIS OF PRESENTATION (Policies) | 9 Months Ended |
Mar. 28, 2021 | |
Accounting Policies [Abstract] | |
Consolidation | The condensed consolidated financial statements include the accounts of Lam Research and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. |
Fiscal Period | The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year will end June 27, 2021 and includes 52 weeks. |
Recent Accounting Pronouncements | Recently Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) released Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326).” The amendment revises the impairment model to utilize an expected loss methodology in place of the previously used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including but not limited to, available for sale debt securities and accounts receivable. The FASB issued a subsequent amendment to the initial guidance in April 2019 and November 2019 within ASU 2019-04 and ASU 2019-11, respectively. The adoption of these standards in the first quarter of fiscal year 2021 did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements (Topic 808).” The amendment clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a good or service that is a distinct unit of account. The amendment also precludes entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The adoption of this standard in the first quarter of fiscal year 2021 did not have a material impact on the Company’s Condensed Consolidated Financial Statements. In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU provides temporary optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued. In January 2021, the FASB issued ASU 2021-01, “ Reference Rate Reform (Topic 848),” which permits entities to apply optional expedients in Topic 848 to derivative instruments modified because of discounting transition resulting from reference rate reform. ASU 2020-04 became effective upon issuance and may be applied prospectively to contract modifications made on or before December 31, 2022. ASU 2021-01 became effective upon issuance and may be applied on a full retrospective basis as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively for contract modifications made on or before December 31, 2022. The Company has not yet applied the relief afforded by these standard amendments and is currently assessing contracts that will require modification due to reference rate reform to which these standard amendments may be applied. |
Inventories | Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. System shipments to customers in Japan, for which title does not transfer until customer acceptance, are classified as finished goods inventory and carried at cost until title transfers. |
Warranties | The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements. |
REVENUE (Tables)
REVENUE (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Contract Transaction Price not yet Recognized as Revenue | The following table summarizes the transaction price for contracts that have not yet been recognized as revenue as of March 28, 2021 and when the Company expects to recognize the amounts as revenue: Less than 1 Year 1-3 Years More than 3 Years Total (In thousands) Deferred revenue $ 661,240 $ 156,040 (1) $ — $ 817,280 (1) This amount is reported in Deferred profit on the Company's Condensed Consolidated Balance Sheets as the customers can demand the liability to be performed at any time. |
Disaggregation of Revenue | The following table presents the Company’s revenues disaggregated between system and its customer support-related revenue: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (In thousands) System revenue $ 2,545,306 $ 1,647,560 $ 7,000,968 $ 4,759,881 Customer support-related revenue and other 1,302,348 856,065 3,480,003 2,492,991 $ 3,847,654 $ 2,503,625 $ 10,480,971 $ 7,252,872 The following table presents the Company’s revenues disaggregated by geographic region: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (In thousands) China $ 1,217,427 $ 792,412 $ 3,600,281 $ 2,142,366 Korea 1,195,711 589,072 2,664,493 1,503,733 Taiwan 545,719 515,485 1,576,109 1,587,848 Japan 262,913 239,751 999,462 721,664 Southeast Asia 260,360 62,800 829,157 460,723 United States 184,887 215,015 460,271 622,399 Europe 180,637 89,090 351,198 214,139 $ 3,847,654 $ 2,503,625 $ 10,480,971 $ 7,252,872 |
Schedule of System Revenues of Primary Markets | The following table presents the percentages of leading- and non-leading-edge equipment and upgrade revenue to each of the primary markets the Company serves: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, Memory 62 % 56 % 62 % 57 % Foundry 31 % 31 % 31 % 31 % Logic/integrated device manufacturing 7 % 13 % 7 % 12 % |
EQUITY-BASED COMPENSATION PLA_2
EQUITY-BASED COMPENSATION PLANS (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Recognized Equity Based Compensation Expense and Related Income Tax Benefit | The Company recognized the following equity-based compensation expense (including expense related to the employee stock purchase plan) and related income tax benefit in the Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Equity-based compensation expense $ 55,746 $ 47,414 $ 163,843 $ 136,044 Income tax benefit recognized related to equity-based compensation expense $ 44,077 $ 24,457 $ 63,866 $ 38,736 |
OTHER EXPENSE, NET (Tables)
OTHER EXPENSE, NET (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Other Income and Expenses [Abstract] | |
Components of Other Expense, Net | The significant components of other expense, net, are as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Interest income $ 4,209 $ 18,856 $ 15,964 $ 76,094 Interest expense (52,236) (41,580) (156,902) (128,190) Gains (losses) on deferred compensation plan-related assets, net 7,520 (33,828) 44,654 (20,135) Foreign exchange gains (losses), net 541 480 (4,597) (2,336) Other, net 4,646 (8,547) (3,172) (16,704) $ (35,320) $ (64,619) $ (104,053) $ (91,271) |
INCOME TAX EXPENSE (Tables)
INCOME TAX EXPENSE (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation | The Company’s provision for income taxes and effective tax rate are as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands, except percentages) Income tax expense $ 88,867 $ 54,714 $ 298,242 $ 271,729 Effective tax rate 7.7 % 8.7 % 9.7 % 14.9 % |
NET INCOME PER SHARE (Tables)
NET INCOME PER SHARE (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share | The following table reconciles the inputs to the basic and diluted computations for net income per share. Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands, except per share data) Numerator: Net income $ 1,071,121 $ 574,781 $ 2,763,801 $ 1,555,080 Denominator: Basic average shares outstanding 142,676 145,301 143,925 144,654 Effect of potential dilutive securities: Employee stock plans 1,415 1,453 1,273 1,390 Convertible notes 518 1,411 725 3,604 Diluted average shares outstanding 144,609 148,165 145,923 149,648 Net income per share - basic $ 7.51 $ 3.96 $ 19.20 $ 10.75 Net income per share - diluted $ 7.41 $ 3.88 $ 18.94 $ 10.39 |
Schedule of Potentially Dilutive Securities Excluded from EPS Calculations | The following potentially dilutive securities were excluded: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Options and RSUs 120 40 40 13 |
FINANCIAL INSTRUMENTS (Tables)
FINANCIAL INSTRUMENTS (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Cash, Cash Equivalents, Investments, Restricted Cash and Investments and Other Assets Measured at Fair Value on Recurring Basis | The following tables set forth the Company’s cash, cash equivalents, investments, restricted cash and investments, and other assets measured at fair value on a recurring basis as of March 28, 2021, and June 28, 2020: March 28, 2021 (Reported Within) Cost Unrealized Unrealized Fair Value Cash and Investments Restricted Other (in thousands) Cash $ 753,473 $ — $ — $ 753,473 $ 750,040 $ — $ 3,433 $ — Time deposits 1,349,934 — — 1,349,934 1,099,907 — 250,027 — Level 1: Money market funds 1,638,280 — — 1,638,280 1,638,280 — — — U.S. Treasury and agencies 385,461 209 (13) 385,657 — 385,657 — — Mutual funds 84,377 10,471 (105) 94,743 — — — 94,743 Level 1 Total 2,108,118 10,680 (118) 2,118,680 1,638,280 385,657 — 94,743 Level 2: Government-sponsored enterprises 3,500 12 — 3,512 — 3,512 — — Foreign government bonds 47,099 43 (1) 47,141 — 47,141 — — Corporate notes and bonds 1,844,375 2,569 (633) 1,846,311 185,139 1,661,172 — — Mortgage backed securities — residential 6,279 74 — 6,353 — 6,353 — — Mortgage backed securities — commercial 12,264 33 (31) 12,266 — 12,266 — — Level 2 Total 1,913,517 2,731 (665) 1,915,583 185,139 1,730,444 — — Total $ 6,125,042 $ 13,411 $ (783) $ 6,137,670 $ 3,673,366 $ 2,116,101 $ 253,460 $ 94,743 June 28, 2020 (Reported Within) Cost Unrealized Unrealized Fair Value Cash and Investments Restricted Other (in thousands) Cash $ 977,862 $ — $ — $ 977,862 $ 973,978 $ — $ 3,884 $ — Time deposits 2,244,655 — — 2,244,655 1,994,628 — 250,027 — Level 1: Money market funds 1,709,350 — — 1,709,350 1,709,350 — — — U.S. Treasury and agencies 552,088 373 (9) 552,452 76,992 475,460 — — Mutual funds 68,784 4,571 (928) 72,427 — — — 72,427 Level 1 Total 2,330,222 4,944 (937) 2,334,229 1,786,342 475,460 — 72,427 Level 2: Government-sponsored enterprises 31,442 12 — 31,454 25,999 5,455 — — Foreign government bonds 10,693 28 (5) 10,716 2,540 8,176 — — Corporate notes and bonds 1,405,615 5,344 (302) 1,410,657 131,685 1,278,972 — — Mortgage backed securities — residential 3,142 71 — 3,213 — 3,213 — — Mortgage backed securities — commercial 23,660 144 — 23,804 — 23,804 — — Level 2 Total 1,474,552 5,599 (307) 1,479,844 160,224 1,319,620 — — Total $ 7,027,291 $ 10,543 $ (1,244) $ 7,036,590 $ 4,915,172 $ 1,795,080 $ 253,911 $ 72,427 |
Schedule of Cash, Cash Equivalents, Investments and Restricted Cash and Investments in Unrealized Loss Positions | The following is an analysis of the Company’s cash, cash equivalents, investments, and restricted cash and investments in unrealized loss positions; as of March 28, 2021 there are no unrealized loss positions with a duration equal to or greater than twelve months: March 28, 2021 Unrealized Losses Fair Value Gross (in thousands) U.S. Treasury and agencies $ 7,958 $ (13) Municipal notes and bonds 6,468 (105) Foreign government bonds 21,259 (1) Corporate notes and bonds 540,915 (633) Mortgage backed securities — commercial 7,599 (31) $ 584,199 $ (783) |
Schedule of Amortized Cost and Fair Value of Cash Equivalents, Investments, Restricted Cash and Investments with Contractual Maturities | The amortized cost and fair value of cash equivalents, investments, and restricted investments with contractual maturities are as follows as of March 28, 2021: Cost Fair (in thousands) Due in one year or less $ 4,270,859 $ 4,271,415 Due after one year through five years 967,417 969,055 Due in more than five years 48,916 48,984 $ 5,287,192 $ 5,289,454 |
Schedule of Total Notional Value of Cash Flow and Balance Sheet Hedge Instruments | The following table provides the total notional value of cash flow hedge instruments outstanding as of March 28, 2021: March 28, (In thousands) Buy Contracts $ 328,737 Sell Contracts 352,034 The following table provides the total notional value of balance sheet hedge instruments outstanding as of March 28, 2021: March 28, (In thousands) Buy Contracts $ 150,554 Sell Contracts 154,595 |
Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations | The effect of derivative instruments designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”), was as follows: Three Months Ended Nine Months Ended March 28, 2021 March 28, 2021 Location of Gain (Loss) Recognized in AOCI (Loss) Gain Gain (Loss) Gain Derivatives in Cash Flow Hedging Relationships (in thousands) Foreign Exchange Contracts Revenue $ 15,285 $ (1,323) $ 6,948 $ (3,598) Foreign Exchange Contracts Cost of goods sold (3,473) 1,355 3,429 3,073 Foreign Exchange Contracts Research and Development (1,319) — 950 — Foreign Exchange Contracts Selling, general, and administrative (1,741) 1,326 4,056 2,649 Interest Rate Contracts Other expense, net — (962) — (2,871) $ 8,752 $ 396 $ 15,383 $ (747) Three Months Ended Nine Months Ended March 29, 2020 March 29, 2020 Location of Gain (Loss) Gain (Loss) Gain (Loss) Gain (Loss) Derivatives in Cash Flow Hedging Relationships (in thousands) Foreign Exchange Contracts Revenue $ 6,334 $ 1,279 $ 9,532 $ 773 Foreign Exchange Contracts Cost of goods sold (2,589) (186) (3,656) (2,086) Foreign Exchange Contracts Selling, general, and administrative (1,394) 6 (1,859) (887) Interest Rate Contracts Other expense, net (40,901) (36) (38,507) (106) $ (38,550) $ 1,063 $ (34,490) $ (2,306) The effect of the Company’s balance sheet hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations was as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, Derivatives Not Designated as Hedging Instruments: Location Gain Loss Gain Loss (in thousands) Foreign Exchange Contracts Other expense, net $ 2,992 $ (6,858) $ 6,895 $ (8,788) |
INVENTORIES (Tables)
INVENTORIES (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | Inventories consist of the following: March 28, June 28, (in thousands) Raw materials $ 1,437,563 $ 1,161,961 Work-in-process 359,402 251,199 Finished goods 755,067 486,864 $ 2,552,032 $ 1,900,024 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The following table provides the Company’s intangible assets, other than goodwill: March 28, 2021 June 28, 2020 Gross Accumulated Net Gross Accumulated Net (in thousands) Customer relationships $ 630,278 $ (569,203) $ 61,075 $ 630,137 $ (532,550) $ 97,587 Existing technology 669,302 (658,632) 10,670 668,992 (654,382) 14,610 Patents and other intangible assets 125,383 (53,864) 71,519 98,342 (42,007) 56,335 Total intangible assets $ 1,424,963 $ (1,281,699) $ 143,264 $ 1,397,471 $ (1,228,939) $ 168,532 |
Estimated Future Amortization Expense of Intangible Assets | The estimated future amortization expense of intangible assets as of March 28, 2021, is reflected in the table below. The table excludes $13.9 million of capitalized costs for internal-use software that have not been placed into service. Fiscal Year Amount (in thousands) 2021 (remaining 3 months) $ 18,019 2022 68,138 2023 22,274 2024 12,089 2025 6,681 Thereafter 2,164 $ 129,365 |
ACCRUED EXPENSES AND OTHER CU_2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consist of the following: March 28, June 28, (in thousands) Accrued compensation $ 442,188 $ 402,401 Warranty reserves 156,059 117,839 Income and other taxes payable 99,021 215,652 Dividend payable 185,390 167,129 Other 409,516 369,634 $ 1,292,174 $ 1,272,655 |
LONG-TERM DEBT AND OTHER BORR_2
LONG-TERM DEBT AND OTHER BORROWINGS (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Outstanding Debt | As of March 28, 2021, and June 28, 2020, the Company’s outstanding debt consisted of the following: March 28, 2021 June 28, 2020 Amount Effective Interest Rate Amount Effective Interest Rate Fixed-rate 2.80% Senior Notes Due June 15, 2021 ("2021 Notes") 800,000 2.95 % 800,000 2.95 % Fixed-rate 3.80% Senior Notes Due March 15, 2025 ("2025 Notes") 500,000 3.87 % 500,000 3.87 % Fixed-rate 3.75% Senior Notes Due March 15, 2026 ("2026 Notes") 750,000 3.86 % 750,000 3.86 % Fixed-rate 4.00% Senior Notes Due March 15, 2029 ("2029 Notes") 1,000,000 4.09 % 1,000,000 4.09 % Fixed-rate 1.90% Senior Note Due June 15, 2030 ("2030 Notes") 750,000 2.01 % 750,000 2.01 % Fixed-rate 2.625% Convertible Notes Due May 15, 2041 ("2041 Notes") 17,289 (1) 4.28 % 48,460 (1) 4.28 % Fixed-rate 4.875% Senior Notes Due March 15, 2049 ("2049 Notes") 750,000 4.93 % 750,000 4.93 % Fixed-rate 2.875% Senior Note Due June 15, 2050 ("2050 Notes") 750,000 2.93 % 750,000 2.93 % Fixed-rate 3.125% Senior Note Due June 15, 2060 ("2060 Notes") 500,000 3.18 % 500,000 3.18 % Total debt outstanding, at par 5,817,289 5,848,460 Unamortized discount (42,443) (53,086) Fair value adjustment - interest rate contracts 7,066 (2) 8,405 (2) Unamortized bond issuance costs (7,649) (8,301) Total debt outstanding, at carrying value $ 5,774,263 $ 5,795,478 Reported as: Current portion of long-term debt $ 813,786 $ 836,107 Long-term debt 4,960,477 4,959,371 Total debt outstanding, at carrying value $ 5,774,263 $ 5,795,478 ____________________________ (1) As of the report date, these notes were convertible at the option of the bondholder. This is a result of the following condition being met: the market value of the Company’s Common Stock was greater than 130% of the convertible notes conversion price for 20 or more of the 30 consecutive trading days preceding the quarter-end. As a result, the 2041 Notes were classified in current liabilities and a portion of the equity component, associated with the convertible notes representing the unamortized discount, was classified in temporary equity on the Company’s Condensed Consolidated Balance Sheets. Additionally, on March 26, 2021, the Company issued a notice of redemption to the existing bondholders, with a redemption date of May 21, 2021. (2) This amount represents a cumulative fair value gain for discontinued hedging relationships, net of an immaterial amount of amortization as of the periods presented. |
Components of Convertible Notes | Selected additional information regarding the 2041 Notes outstanding as of March 28, 2021, and June 28, 2020, is as follows: March 28, June 28, 2041 Notes 2041 Notes (in thousands, except years, percentages, conversion rate, and conversion price) Carrying amount of permanent equity component, net of tax $ 161,612 $ 161,467 Carrying amount of temporary equity component, net of tax $ 3,217 $ 10,995 Remaining amortization period (years) 20.1 20.9 Fair Value of Notes (Level 2) $ 319,495 Conversion rate (shares of common stock per $1,000 principal amount of notes) 31.8009 Conversion price (per share of common stock) $ 31.45 If-converted value in excess of par value $ 303,924 Estimated share dilution using average quarterly stock price $538.79 per share 518 |
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments | Selected additional information regarding the Senior Notes outstanding as of March 28, 2021, is as follows: Remaining Amortization period Fair Value of Notes (Level 2) (years) (in thousands) 2021 Notes 0.2 $ 802,480 2025 Notes 4.0 $ 550,435 2026 Notes 5.0 $ 835,095 2029 Notes 8.0 $ 1,139,390 2030 Notes 9.2 $ 729,968 2049 Notes 28.0 $ 973,500 2050 Notes 29.2 $ 711,263 2060 Notes 39.2 $ 484,215 |
Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes | The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the debt discount, issuance costs, and effective portion of interest rate contracts with respect to the Senior Notes, convertible notes, commercial paper, and the revolving credit facility during the three and nine months ended March 28, 2021 and March 29, 2020. Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Contractual interest coupon $ 49,487 $ 40,409 $ 148,573 $ 122,196 Amortization of interest discount 998 953 3,011 3,346 Amortization of issuance costs 414 408 1,238 1,238 Effect of interest rate contracts, net 516 59 1,533 889 Total interest cost recognized $ 51,415 $ 41,829 $ 154,355 $ 127,669 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Warranties | Changes in the Company’s product warranty reserves were as follows: Three Months Ended Nine Months Ended March 28, March 29, March 28, March 29, (in thousands) Balance at beginning of period $ 153,214 $ 118,193 $ 129,197 $ 127,932 Warranties issued during the period 60,223 44,898 163,869 115,798 Settlements made during the period (45,792) (31,647) (123,462) (98,563) Changes in liability for pre-existing warranties 4,801 (1,252) 2,842 (14,975) Balance at end of period $ 172,446 $ 130,192 $ 172,446 $ 130,192 |
STOCK REPURCHASE PROGRAM (Table
STOCK REPURCHASE PROGRAM (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Equity [Abstract] | |
Repurchases Under the Repurchase Program | Repurchases under the repurchase program were as follows during the periods indicated: Period Total Number of Total Cost of Average Price (1) Amount (in thousands, except per share data) Available balance as of June 28, 2020 $ 1,773,427 Quarter ended September 27, 2020 1,344 $ 461,998 $ 343.73 $ 1,311,429 Board authorization, $5 billion increase, November 2020 $ 6,311,429 Quarter ended December 27, 2020 1,789 $ 724,485 $ 404.98 $ 5,586,944 Quarter ended March 28, 2021 1,474 $ 925,099 $ 519.30 $ 4,661,845 (1) Average price paid per share excludes the effect of accelerated share repurchases. See additional disclosure below regarding the Company’s accelerated share repurchase activity during the nine months ended March 28, 2021. |
ACCUMULATED OTHER COMPREHENSI_2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) | 9 Months Ended |
Mar. 28, 2021 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Loss | The components of accumulated other comprehensive loss, net of tax at March 28, 2021, as well as the activity for the nine months ending March 28, 2021, were as follows: Accumulated Foreign Currency Translation Adjustment Accumulated Accumulated Accumulated Total (in thousands) Balance at June 28, 2020 $ (45,811) $ (32,796) $ 4,923 $ (20,527) $ (94,211) Other comprehensive income (loss) before reclassifications 20,231 12,546 (3,667) 234 29,344 Losses reclassified from accumulated other comprehensive loss to net income — 843 (1) 727 (2) — 1,570 Net current-period other comprehensive income (loss) 20,231 13,389 (2,940) 234 30,914 Balance at March 28, 2021 $ (25,580) $ (19,407) $ 1,983 $ (20,293) $ (63,297) (1) Amount of after-tax loss reclassified from AOCI into net income is not material in the aggregate, or to any individual location in our Condensed Consolidated Statements of Operations. (2) Amount of after-tax loss reclassified from accumulated other comprehensive income into net income located in other expense, net. |
REVENUE - Additional Informatio
REVENUE - Additional Information (Details) $ in Millions | 3 Months Ended | 9 Months Ended |
Mar. 28, 2021USD ($)segmentregionmarket | Mar. 28, 2021USD ($) | |
Revenue from Contract with Customer [Abstract] | ||
Revenue recognized | $ | $ 69.1 | $ 427.2 |
Number reportable business segment | segment | 1 | |
Number of operating geographic regions | region | 7 | |
Number of primary markets | market | 3 |
REVENUE - Summary of Contract T
REVENUE - Summary of Contract Transaction Price not yet Recognized as Revenue (Details) $ in Thousands | Mar. 28, 2021USD ($) |
Revenue from Contract with Customer [Abstract] | |
Deferred revenue | $ 817,280 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-03-29 | |
Revenue from Contract with Customer [Abstract] | |
Deferred revenue | $ 661,240 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of satisfaction | 3 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-06-28 | |
Revenue from Contract with Customer [Abstract] | |
Deferred revenue | $ 156,040 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of satisfaction | 2 years |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-06-24 | |
Revenue from Contract with Customer [Abstract] | |
Deferred revenue | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Deferred revenue, expected timing of satisfaction |
REVENUE - Disaggregation of Rev
REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 3,847,654 | $ 2,503,625 | $ 10,480,971 | $ 7,252,872 |
China | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 1,217,427 | 792,412 | 3,600,281 | 2,142,366 |
Korea | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 1,195,711 | 589,072 | 2,664,493 | 1,503,733 |
Taiwan | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 545,719 | 515,485 | 1,576,109 | 1,587,848 |
Japan | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 262,913 | 239,751 | 999,462 | 721,664 |
Southeast Asia | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 260,360 | 62,800 | 829,157 | 460,723 |
United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 184,887 | 215,015 | 460,271 | 622,399 |
Europe | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 180,637 | 89,090 | 351,198 | 214,139 |
System revenue | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | 2,545,306 | 1,647,560 | 7,000,968 | 4,759,881 |
Customer support-related revenue and other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue | $ 1,302,348 | $ 856,065 | $ 3,480,003 | $ 2,492,991 |
REVENUE - Schedule of System Re
REVENUE - Schedule of System Revenues of Primary Markets (Details) - Equipment and upgrade revenue | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Memory | ||||
Concentration Risk [Line Items] | ||||
Primary market revenue, percent | 62.00% | 56.00% | 62.00% | 57.00% |
Foundry | ||||
Concentration Risk [Line Items] | ||||
Primary market revenue, percent | 31.00% | 31.00% | 31.00% | 31.00% |
Logic/integrated device manufacturing | ||||
Concentration Risk [Line Items] | ||||
Primary market revenue, percent | 7.00% | 13.00% | 7.00% | 12.00% |
EQUITY-BASED COMPENSATION PLA_3
EQUITY-BASED COMPENSATION PLANS - Additional Information (Details) | 3 Months Ended |
Mar. 28, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Vesting period (in years) | 3 years |
EQUITY-BASED COMPENSATION PLA_4
EQUITY-BASED COMPENSATION PLANS - Recognized Equity-Based Compensation Expenses and Related Income Tax Benefit (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Share-based Payment Arrangement [Abstract] | ||||
Equity-based compensation expense | $ 55,746 | $ 47,414 | $ 163,843 | $ 136,044 |
Income tax benefit recognized related to equity-based compensation expense | $ 44,077 | $ 24,457 | $ 63,866 | $ 38,736 |
OTHER EXPENSE, NET (Details)
OTHER EXPENSE, NET (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Other Income and Expenses [Abstract] | ||||
Interest income | $ 4,209 | $ 18,856 | $ 15,964 | $ 76,094 |
Interest expense | (52,236) | (41,580) | (156,902) | (128,190) |
Gains (losses) on deferred compensation plan-related assets, net | 7,520 | (33,828) | 44,654 | (20,135) |
Foreign exchange gains (losses), net | 541 | 480 | (4,597) | (2,336) |
Other, net | 4,646 | (8,547) | (3,172) | (16,704) |
Other expense, net | $ (35,320) | $ (64,619) | $ (104,053) | $ (91,271) |
INCOME TAX EXPENSE (Details)
INCOME TAX EXPENSE (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Income Tax Disclosure [Abstract] | ||||
Income tax expense | $ 88,867 | $ 54,714 | $ 298,242 | $ 271,729 |
Effective tax rate | 7.70% | 8.70% | 9.70% | 14.90% |
Tax examinations or lapses of statute of limitation | ||||
Income Tax Contingency [Line Items] | ||||
Estimated unrecognized tax benefits reduction | $ 7,400 | $ 7,400 |
NET INCOME PER SHARE - Schedule
NET INCOME PER SHARE - Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Numerator: | ||||
Net income | $ 1,071,121 | $ 574,781 | $ 2,763,801 | $ 1,555,080 |
Denominator: | ||||
Basic average shares outstanding (in shares) | 142,676 | 145,301 | 143,925 | 144,654 |
Effect of potential dilutive securities: | ||||
Employee stock plans (in shares) | 1,415 | 1,453 | 1,273 | 1,390 |
Convertible notes (in shares) | 518 | 1,411 | 725 | 3,604 |
Diluted average shares outstanding (in shares) | 144,609 | 148,165 | 145,923 | 149,648 |
Net income per share - basic (in dollars per share) | $ 7.51 | $ 3.96 | $ 19.20 | $ 10.75 |
Net income per share - diluted (in dollars per share) | $ 7.41 | $ 3.88 | $ 18.94 | $ 10.39 |
NET INCOME PER SHARE - Schedu_2
NET INCOME PER SHARE - Schedule of Potentially Dilutive Securities Excluded from EPS Calculations (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Options and RSUs | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Number of potentially dilutive securities (in shares) | 120 | 40 | 40 | 13 |
FINANCIAL INSTRUMENTS - Schedul
FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents, Investments, Restricted Cash and Investments and Other Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 | Mar. 29, 2020 | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | $ 5,287,192 | |||
Total cost | 6,125,042 | $ 7,027,291 | ||
Total, unrealized gain | 13,411 | 10,543 | ||
Total unrealized (loss) | (783) | (1,244) | ||
Total fair value | 6,137,670 | 7,036,590 | ||
Cash and Cash Equivalents | 3,673,366 | 4,915,172 | [1] | $ 3,961,586 |
Investments | 2,116,101 | 1,795,080 | [1] | |
Restricted cash and investments | 253,460 | 253,911 | [1] | |
Other Assets | 94,743 | 72,427 | ||
Level 1 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Total cost | 2,108,118 | 2,330,222 | ||
Total, unrealized gain | 10,680 | 4,944 | ||
Total unrealized (loss) | (118) | (937) | ||
Total fair value | 2,118,680 | 2,334,229 | ||
Cash and Cash Equivalents | 1,638,280 | 1,786,342 | ||
Investments | 385,657 | 475,460 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 94,743 | 72,427 | ||
Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Total cost | 1,913,517 | 1,474,552 | ||
Total, unrealized gain | 2,731 | 5,599 | ||
Total unrealized (loss) | (665) | (307) | ||
Total fair value | 1,915,583 | 1,479,844 | ||
Cash and Cash Equivalents | 185,139 | 160,224 | ||
Investments | 1,730,444 | 1,319,620 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Cash | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Cash and cash equivalents at fair value | 753,473 | 977,862 | ||
Cash and Cash Equivalents | 750,040 | 973,978 | ||
Investments | 0 | 0 | ||
Restricted cash and investments | 3,433 | 3,884 | ||
Other Assets | 0 | 0 | ||
Time deposits | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Cash and cash equivalents at fair value | 1,349,934 | 2,244,655 | ||
Cash and Cash Equivalents | 1,099,907 | 1,994,628 | ||
Investments | 0 | 0 | ||
Restricted cash and investments | 250,027 | 250,027 | ||
Other Assets | 0 | 0 | ||
Money market funds | Level 1 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 1,638,280 | 1,709,350 | ||
Debt securities, unrealized gain | 0 | 0 | ||
Debt securities, unrealized (loss) | 0 | 0 | ||
Debt securities, fair value | 1,638,280 | 1,709,350 | ||
Cash and Cash Equivalents | 1,638,280 | 1,709,350 | ||
Investments | 0 | 0 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
U.S. Treasury and agencies | Level 1 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 385,461 | 552,088 | ||
Debt securities, unrealized gain | 209 | 373 | ||
Debt securities, unrealized (loss) | (13) | (9) | ||
Debt securities, fair value | 385,657 | 552,452 | ||
Cash and Cash Equivalents | 0 | 76,992 | ||
Investments | 385,657 | 475,460 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Mutual funds | Level 1 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Trading securities, cost | 84,377 | 68,784 | ||
Trading securities, unrealized gain | 10,471 | 4,571 | ||
Trading securities, unrealized (loss) | (105) | (928) | ||
Trading securities, fair value | 94,743 | 72,427 | ||
Cash and Cash Equivalents | 0 | 0 | ||
Investments | 0 | 0 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 94,743 | 72,427 | ||
Government-sponsored enterprises | Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 3,500 | 31,442 | ||
Debt securities, unrealized gain | 12 | 12 | ||
Debt securities, unrealized (loss) | 0 | 0 | ||
Debt securities, fair value | 3,512 | 31,454 | ||
Cash and Cash Equivalents | 0 | 25,999 | ||
Investments | 3,512 | 5,455 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Foreign government bonds | Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 47,099 | 10,693 | ||
Debt securities, unrealized gain | 43 | 28 | ||
Debt securities, unrealized (loss) | (1) | (5) | ||
Debt securities, fair value | 47,141 | 10,716 | ||
Cash and Cash Equivalents | 0 | 2,540 | ||
Investments | 47,141 | 8,176 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Corporate notes and bonds | Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 1,844,375 | 1,405,615 | ||
Debt securities, unrealized gain | 2,569 | 5,344 | ||
Debt securities, unrealized (loss) | (633) | (302) | ||
Debt securities, fair value | 1,846,311 | 1,410,657 | ||
Cash and Cash Equivalents | 185,139 | 131,685 | ||
Investments | 1,661,172 | 1,278,972 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Mortgage backed securities — residential | Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 6,279 | 3,142 | ||
Debt securities, unrealized gain | 74 | 71 | ||
Debt securities, unrealized (loss) | 0 | 0 | ||
Debt securities, fair value | 6,353 | 3,213 | ||
Cash and Cash Equivalents | 0 | 0 | ||
Investments | 6,353 | 3,213 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | 0 | 0 | ||
Mortgage backed securities — commercial | Level 2 | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||
Debt securities, cost | 12,264 | 23,660 | ||
Debt securities, unrealized gain | 33 | 144 | ||
Debt securities, unrealized (loss) | (31) | 0 | ||
Debt securities, fair value | 12,266 | 23,804 | ||
Cash and Cash Equivalents | 0 | 0 | ||
Investments | 12,266 | 23,804 | ||
Restricted cash and investments | 0 | 0 | ||
Other Assets | $ 0 | $ 0 | ||
[1] | Derived from audited financial statements |
FINANCIAL INSTRUMENTS - Additio
FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Fair Value Disclosures [Abstract] | ||||
Other than temporary impairment losses, investments | $ 0 | |||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Insignificant realized gains/losses | $ 0 | $ 0 | $ 0 | $ 0 |
Cash Flow Hedges | Minimum | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Foreign currency cash flow hedge, expiration period | 12 months | |||
Cash Flow Hedges | Maximum | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Foreign currency cash flow hedge, expiration period | 24 months |
FINANCIAL INSTRUMENTS - Sched_2
FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents, Investments and Restricted Cash and Investments Unrealized Loss Positions (Details) $ in Thousands | Mar. 28, 2021USD ($) |
Fair Value | |
Unrealized Losses Less than 12 Months | $ 584,199 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | (783) |
U.S. Treasury and agencies | |
Fair Value | |
Unrealized Losses Less than 12 Months | 7,958 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | (13) |
Municipal notes and bonds | |
Fair Value | |
Unrealized Losses Less than 12 Months | 6,468 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | (105) |
Foreign government bonds | |
Fair Value | |
Unrealized Losses Less than 12 Months | 21,259 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | (1) |
Corporate notes and bonds | |
Fair Value | |
Unrealized Losses Less than 12 Months | 540,915 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | (633) |
Mortgage backed securities — commercial | |
Fair Value | |
Unrealized Losses Less than 12 Months | 7,599 |
Gross Unrealized Loss | |
Unrealized Losses Less than 12 Months | $ (31) |
FINANCIAL INSTRUMENTS - Sched_3
FINANCIAL INSTRUMENTS - Schedule of Amortized Cost and Fair Value of Cash Equivalents, Investments, and Restricted Cash and Investments with Contractual Maturities (Details) $ in Thousands | Mar. 28, 2021USD ($) |
Cost | |
Due in one year or less | $ 4,270,859 |
Due after one year through five years | 967,417 |
Due in more than five years | 48,916 |
Debt securities, cost | 5,287,192 |
Fair Value | |
Due in one year or less | 4,271,415 |
Due after one year through five years | 969,055 |
Due in more than five years | 48,984 |
Total | $ 5,289,454 |
FINANCIAL INSTRUMENTS - Sched_4
FINANCIAL INSTRUMENTS - Schedule of Total Notional Value of Cash Flow and Balance Sheet Hedge Instruments (Details) - Foreign Exchange Contract - Foreign currency forward contracts $ in Thousands | Mar. 28, 2021USD ($) |
Designated as Hedging Instrument | Buy Contracts | |
Derivative [Line Items] | |
Derivative notional amount | $ 328,737 |
Designated as Hedging Instrument | Sell Contracts | |
Derivative [Line Items] | |
Derivative notional amount | 352,034 |
Derivatives not designated as hedging instruments | Buy Contracts | |
Derivative [Line Items] | |
Derivative notional amount | 150,554 |
Derivatives not designated as hedging instruments | Sell Contracts | |
Derivative [Line Items] | |
Derivative notional amount | $ 154,595 |
FINANCIAL INSTRUMENTS - Sched_5
FINANCIAL INSTRUMENTS - Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations Including Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Foreign Exchange Contracts | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | $ 8,752 | $ (38,550) | $ 15,383 | $ (34,490) |
(Loss) Gain Reclassified from AOCI into Net Income | 396 | 1,063 | (747) | (2,306) |
Foreign Exchange Contracts | Revenue | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | 15,285 | 6,334 | 6,948 | 9,532 |
(Loss) Gain Reclassified from AOCI into Net Income | (1,323) | 1,279 | (3,598) | 773 |
Foreign Exchange Contracts | Cost of goods sold | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | (3,473) | (2,589) | 3,429 | (3,656) |
(Loss) Gain Reclassified from AOCI into Net Income | 1,355 | (186) | 3,073 | (2,086) |
Foreign Exchange Contracts | Research and Development | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | (1,319) | 950 | ||
(Loss) Gain Reclassified from AOCI into Net Income | 0 | 0 | ||
Foreign Exchange Contracts | Selling, general, and administrative | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | (1,741) | (1,394) | 4,056 | (1,859) |
(Loss) Gain Reclassified from AOCI into Net Income | 1,326 | 6 | 2,649 | (887) |
Foreign Exchange Contracts | Other expense, net | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in Net Income | 2,992 | (6,858) | 6,895 | (8,788) |
Interest Rate Contracts | Other expense, net | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Gain (Loss) Recognized in AOCI | 0 | (40,901) | 0 | (38,507) |
(Loss) Gain Reclassified from AOCI into Net Income | $ (962) | $ (36) | $ (2,871) | $ (106) |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 | |
Inventory Disclosure [Abstract] | |||
Raw materials | $ 1,437,563 | $ 1,161,961 | |
Work-in-process | 359,402 | 251,199 | |
Finished goods | 755,067 | 486,864 | |
Total inventories | $ 2,552,032 | $ 1,900,024 | [1] |
[1] | Derived from audited financial statements |
GOODWILL AND INTANGIBLE ASSET_2
GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | Jun. 28, 2020 | ||
Goodwill and Intangible Assets Disclosure [Abstract] | ||||||
Goodwill | $ 1,489,990 | $ 1,489,990 | $ 1,484,436 | [1] | ||
Tax deductible goodwill | 61,100 | 61,100 | $ 61,100 | |||
Intangible asset amortization expense | 17,900 | $ 16,600 | 52,300 | $ 49,300 | ||
Capitalized costs for internal-use software | $ 13,900 | $ 13,900 | ||||
[1] | Derived from audited financial statements |
GOODWILL AND INTANGIBLE ASSET_3
GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 | |
Finite-Lived Intangible Assets [Line Items] | |||
Gross | $ 1,424,963 | $ 1,397,471 | |
Accumulated Amortization | (1,281,699) | (1,228,939) | |
Net | 143,264 | 168,532 | [1] |
Customer relationships | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross | 630,278 | 630,137 | |
Accumulated Amortization | (569,203) | (532,550) | |
Net | 61,075 | 97,587 | |
Existing technology | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross | 669,302 | 668,992 | |
Accumulated Amortization | (658,632) | (654,382) | |
Net | 10,670 | 14,610 | |
Patents and other intangible assets | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross | 125,383 | 98,342 | |
Accumulated Amortization | (53,864) | (42,007) | |
Net | $ 71,519 | $ 56,335 | |
[1] | Derived from audited financial statements |
GOODWILL AND INTANGIBLE ASSET_4
GOODWILL AND INTANGIBLE ASSETS - Estimated Future Amortization Expense of Intangible Assets (Details) $ in Thousands | Mar. 28, 2021USD ($) |
Fiscal Year | |
2021 (remaining 3 months) | $ 18,019 |
2022 | 68,138 |
2023 | 22,274 |
2024 | 12,089 |
2025 | 6,681 |
Thereafter | 2,164 |
Net | $ 129,365 |
ACCRUED EXPENSES AND OTHER CU_3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands | Mar. 28, 2021 | Jun. 28, 2020 | |
Payables and Accruals [Abstract] | |||
Accrued compensation | $ 442,188 | $ 402,401 | |
Warranty reserves | 156,059 | 117,839 | |
Income and other taxes payable | 99,021 | 215,652 | |
Dividend payable | 185,390 | 167,129 | |
Other | 409,516 | 369,634 | |
Accrued expenses and other current liabilities | $ 1,292,174 | $ 1,272,655 | [1] |
[1] | Derived from audited financial statements |
LONG-TERM DEBT AND OTHER BORR_3
LONG-TERM DEBT AND OTHER BORROWINGS - Schedule of Outstanding Debt (Details) $ in Thousands | 9 Months Ended | ||||||
Mar. 28, 2021USD ($)d | Jun. 28, 2020USD ($) | May 05, 2020 | Mar. 04, 2019 | Jun. 07, 2016 | Mar. 12, 2015 | Jun. 30, 2012 | |
Debt Instrument [Line Items] | |||||||
Total debt outstanding, at par | $ 5,817,289 | $ 5,848,460 | |||||
Unamortized discount | (42,443) | (53,086) | |||||
Fair value adjustment - interest rate contracts | 7,066 | 8,405 | |||||
Unamortized bond issuance costs | (7,649) | (8,301) | |||||
Total debt outstanding, at carrying value | 5,774,263 | 5,795,478 | |||||
Current portion of long-term debt | 813,786 | 836,107 | |||||
Long-term debt | $ 4,960,477 | $ 4,959,371 | |||||
Senior notes | Fixed-rate 2.80% Senior Notes Due June 15, 2021 ("2021 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 2.80% | 2.80% | |||||
Effective Interest Rate | 2.95% | 2.95% | |||||
Amount | $ 800,000 | $ 800,000 | |||||
Senior notes | Fixed-rate 3.80% Senior Notes Due March 15, 2025 ("2025 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 3.80% | 3.80% | |||||
Effective Interest Rate | 3.87% | 3.87% | |||||
Amount | $ 500,000 | $ 500,000 | |||||
Senior notes | Fixed-rate 3.75% Senior Notes Due March 15, 2026 ("2026 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 3.75% | 3.75% | |||||
Effective Interest Rate | 3.86% | 3.86% | |||||
Amount | $ 750,000 | $ 750,000 | |||||
Senior notes | Fixed-rate 4.00% Senior Notes Due March 15, 2029 ("2029 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 4.00% | 4.00% | |||||
Effective Interest Rate | 4.09% | 4.09% | |||||
Amount | $ 1,000,000 | $ 1,000,000 | |||||
Senior notes | Fixed-rate 1.90% Senior Note Due June 15, 2030 ("2030 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 1.90% | 1.90% | |||||
Effective Interest Rate | 2.01% | 2.01% | |||||
Amount | $ 750,000 | $ 750,000 | |||||
Senior notes | Fixed-rate 4.875% Senior Notes Due March 15, 2049 ("2049 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 4.875% | 4.875% | |||||
Effective Interest Rate | 4.93% | 4.93% | |||||
Amount | $ 750,000 | $ 750,000 | |||||
Senior notes | Fixed-rate 2.875% Senior Note Due June 15, 2050 ("2050 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 2.875% | 2.875% | |||||
Effective Interest Rate | 2.93% | 2.93% | |||||
Amount | $ 750,000 | $ 750,000 | |||||
Senior notes | Fixed-rate 3.125% Senior Note Due June 15, 2060 ("2060 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 3.125% | 3.125% | |||||
Effective Interest Rate | 3.18% | 3.18% | |||||
Amount | $ 500,000 | $ 500,000 | |||||
Convertible debt | Fixed-rate 2.625% Convertible Notes Due May 15, 2041 ("2041 Notes") | |||||||
Debt Instrument [Line Items] | |||||||
Senior notes interest rate | 2.625% | 2.625% | |||||
Effective Interest Rate | 4.28% | 4.28% | |||||
Amount | $ 17,289 | $ 48,460 | |||||
Stock price percentage of conversion price | 130.00% | ||||||
Number of days on which common stock sale price was greater than or equal to 130% of conversion price, in a period of 30 consecutive trading days ending on the last trading day of the preceding the quarter | d | 20 | ||||||
Number of consecutive trading days period required | d | 30 |
LONG-TERM DEBT AND OTHER BORR_4
LONG-TERM DEBT AND OTHER BORROWINGS - Convertible Senior Notes (Details) - Fixed-rate 2.625% Convertible Notes Due May 15, 2041 ("2041 Notes") - Convertible debt - USD ($) | 1 Months Ended | 3 Months Ended | 4 Months Ended | 9 Months Ended | |
Jun. 30, 2012 | Mar. 28, 2021 | Apr. 28, 2021 | Mar. 28, 2021 | Jun. 28, 2020 | |
Debt Instrument [Line Items] | |||||
Principal amount | $ 700,000,000 | ||||
Senior notes interest rate | 2.625% | 2.625% | 2.625% | ||
Conversion of notes | $ 9,600,000 | $ 31,200,000 | |||
Long-term debt | $ 17,289,000 | $ 17,289,000 | $ 48,460,000 | ||
Conversion of 2041 notes | Subsequent event | |||||
Debt Instrument [Line Items] | |||||
Conversion of notes | $ 0 | ||||
Maximum | |||||
Debt Instrument [Line Items] | |||||
Maximum amount of contingent interest rate | 0.60% |
LONG-TERM DEBT AND OTHER BORR_5
LONG-TERM DEBT AND OTHER BORROWINGS - Components of Convertible Senior Notes (Details) - Convertible debt - Fixed-rate 2.625% Convertible Notes Due May 15, 2041 ("2041 Notes") $ / shares in Units, shares in Thousands | 9 Months Ended | 12 Months Ended |
Mar. 28, 2021USD ($)$ / sharesshares | Jun. 28, 2020USD ($) | |
Debt Instrument [Line Items] | ||
Remaining amortization period (years) | 20 years 1 month 6 days | 20 years 10 months 24 days |
Fair Value of Notes (Level 2) | $ 319,495,000 | |
Conversion rate (shares of common stock per $1,000 principal amount of notes) | $ 1,000 | |
Conversion rate (shares of common stock per $1,000 principal amount of notes) | 31.8009 | |
Conversion price (per share of common stock) (in dollars per share) | $ / shares | $ 31.45 | |
If-converted value in excess of par value | $ 303,924,000 | |
Estimated share dilution using average quarterly stock price $538.79 per share | shares | 518 | |
Share price (in dollars per share) | $ / shares | $ 538.79 | |
Permanent Equity | ||
Debt Instrument [Line Items] | ||
Carrying amount of equity component, net of tax | $ 161,612,000 | $ 161,467,000 |
Temporary Equity | ||
Debt Instrument [Line Items] | ||
Carrying amount of equity component, net of tax | $ 3,217,000 | $ 10,995,000 |
LONG-TERM DEBT AND OTHER BORR_6
LONG-TERM DEBT AND OTHER BORROWINGS - Senior Notes (Details) - Senior notes - USD ($) | 9 Months Ended | ||||
Mar. 28, 2021 | May 05, 2020 | Mar. 04, 2019 | Jun. 07, 2016 | Mar. 12, 2015 | |
Debt Instrument [Line Items] | |||||
Debt instrument, redemption price percent | 100.00% | ||||
2030 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 750,000,000 | ||||
Senior notes interest rate | 1.90% | 1.90% | |||
2050 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 750,000,000 | ||||
Senior notes interest rate | 2.875% | 2.875% | |||
2060 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 500,000,000 | ||||
Senior notes interest rate | 3.125% | 3.125% | |||
2026 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 750,000,000 | ||||
Senior notes interest rate | 3.75% | 3.75% | |||
2029 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 1,000,000,000 | ||||
Senior notes interest rate | 4.00% | 4.00% | |||
2049 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 750,000,000 | ||||
Senior notes interest rate | 4.875% | 4.875% | |||
2025 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 500,000,000 | ||||
Senior notes interest rate | 3.80% | 3.80% | |||
2021 Notes | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 800,000,000 | ||||
Senior notes interest rate | 2.80% | 2.80% | |||
Debt instrument, redemption price upon occurrence of certain events, percent | 101.00% |
LONG-TERM DEBT AND OTHER BORR_7
LONG-TERM DEBT AND OTHER BORROWINGS - Schedule of Additional Senior Notes Information (Details) $ in Thousands | 9 Months Ended |
Mar. 28, 2021USD ($) | |
2021 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 2 months 12 days |
2021 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 802,480 |
2025 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 4 years |
2025 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 550,435 |
2026 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 5 years |
2026 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 835,095 |
2029 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 8 years |
2029 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 1,139,390 |
2030 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 9 years 2 months 12 days |
2030 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 729,968 |
2049 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 28 years |
2049 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 973,500 |
2050 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 29 years 2 months 12 days |
2050 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 711,263 |
2060 Notes | |
Debt Instrument [Line Items] | |
Remaining amortization period (in years) | 39 years 2 months 12 days |
2060 Notes | Level 2 | |
Debt Instrument [Line Items] | |
Fair Value of Notes (Level 2) | $ 484,215 |
LONG-TERM DEBT AND OTHER BORR_8
LONG-TERM DEBT AND OTHER BORROWINGS - Revolving Credit Facility (Details) - Revolving credit facility - USD ($) | Feb. 25, 2019 | Mar. 28, 2021 |
Extinguishment of Debt [Line Items] | ||
Revolving unsecured credit facility | $ 1,250,000,000 | |
Additional increase in the facility, available expansion | 600,000,000 | |
Revolving unsecured credit facility, available expansion | $ 1,850,000,000 | |
Borrowings outstanding | $ 0 | |
Federal Funds Rate | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 0.50% | |
One-month LIBOR | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 1.00% | |
One-month LIBOR | Minimum | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 0.00% | |
One-month LIBOR | Maximum | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 0.50% | |
LIBOR | Minimum | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 0.90% | |
LIBOR | Maximum | ||
Extinguishment of Debt [Line Items] | ||
Variable interest spread | 1.50% |
LONG-TERM DEBT AND OTHER BORR_9
LONG-TERM DEBT AND OTHER BORROWINGS - Commercial Paper Program (Details) - Commercial paper - USD ($) | Mar. 28, 2021 | Jun. 28, 2020 | Nov. 13, 2017 |
Line of Credit Facility [Line Items] | |||
Unsecured private placement commercial paper notes, maximum aggregate principal | $ 1,250,000,000 | ||
Borrowings outstanding | $ 0 | $ 0 |
LONG-TERM DEBT AND OTHER BOR_10
LONG-TERM DEBT AND OTHER BORROWINGS - Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Debt Disclosure [Abstract] | ||||
Contractual interest coupon | $ 49,487 | $ 40,409 | $ 148,573 | $ 122,196 |
Amortization of interest discount | 998 | 953 | 3,011 | 3,346 |
Amortization of issuance costs | 414 | 408 | 1,238 | 1,238 |
Effect of interest rate contracts, net | 516 | 59 | 1,533 | 889 |
Total interest cost recognized | $ 51,415 | $ 41,829 | $ 154,355 | $ 127,669 |
LEASES (Details)
LEASES (Details) - USD ($) | Mar. 28, 2021 | Sep. 21, 2020 | Jun. 28, 2020 | [1] |
Guarantor Obligations [Line Items] | ||||
Restricted cash and investments | $ 253,460,000 | $ 253,911,000 | ||
California Facility Leases | ||||
Guarantor Obligations [Line Items] | ||||
Lease renewal term | 7 years | |||
Right of use assets | $ 31,400,000 | |||
Finance lease obligations | 29,800,000 | |||
Finance lease obligations, current | $ 3,100,000 | |||
California Facility Leases | Maximum | ||||
Guarantor Obligations [Line Items] | ||||
Residual value of operating lease, maximum | 298,400,000 | |||
Operating Lease Cash Collateral | ||||
Guarantor Obligations [Line Items] | ||||
Restricted cash and investments | $ 250,000,000 | |||
[1] | Derived from audited financial statements |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Thousands | Mar. 28, 2021 | Dec. 27, 2020 | Jun. 28, 2020 | Mar. 29, 2020 | Dec. 29, 2019 | Jun. 30, 2019 |
Loss Contingencies [Line Items] | ||||||
Warranty reserves | $ 172,446 | $ 153,214 | $ 129,197 | $ 130,192 | $ 118,193 | $ 127,932 |
Other long-term liabilities | ||||||
Loss Contingencies [Line Items] | ||||||
Warranty reserves | 16,400 | |||||
Letters of Credit | ||||||
Loss Contingencies [Line Items] | ||||||
Guarantee obligation maximum exposure | $ 73,200 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES - Schedule of Changes in Product Warranty Reserves (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 28, 2021 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | |
Changes in Product Warranty Reserve | ||||
Balance at beginning of period | $ 153,214 | $ 118,193 | $ 129,197 | $ 127,932 |
Warranties issued during the period | 60,223 | 44,898 | 163,869 | 115,798 |
Settlements made during the period | (45,792) | (31,647) | (123,462) | (98,563) |
Changes in liability for pre-existing warranties | 4,801 | (1,252) | 2,842 | (14,975) |
Balance at end of period | $ 172,446 | $ 130,192 | $ 172,446 | $ 130,192 |
STOCK REPURCHASE PROGRAM - Addi
STOCK REPURCHASE PROGRAM - Additional Information (Details) - USD ($) shares in Thousands | Feb. 11, 2021 | Nov. 30, 2020 | Mar. 28, 2021 | Dec. 27, 2020 | Sep. 27, 2020 | Mar. 28, 2021 |
Equity, Class of Treasury Stock [Line Items] | ||||||
Net shares of settlements to cover tax withholding obligations (in shares) | 257 | 280 | ||||
Amount paid for shares under net share settlements | $ 152,300,000 | $ 160,600,000 | ||||
Stock repurchase program | ||||||
Equity, Class of Treasury Stock [Line Items] | ||||||
Board authorized increase | $ 5,000,000,000 | |||||
Total Number of Shares Repurchased (in shares) | 1,474 | 1,789 | 1,344 | |||
February 2021 ASR | ||||||
Equity, Class of Treasury Stock [Line Items] | ||||||
Accelerated Share Repurchases, Authorized Amount | $ 500,000,000 | |||||
Total Number of Shares Repurchased (in shares) | 655 | |||||
Percent of prepayment amount | 75.00% |
STOCK REPURCHASE PROGRAM - Repu
STOCK REPURCHASE PROGRAM - Repurchases Under the Repurchase Program (Details) - USD ($) $ / shares in Units, shares in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Nov. 30, 2020 | Mar. 28, 2021 | Dec. 27, 2020 | Sep. 27, 2020 | Mar. 29, 2020 | Mar. 28, 2021 | Mar. 29, 2020 | Jun. 28, 2020 | |
Equity, Class of Treasury Stock [Line Items] | ||||||||
Total Cost of Repurchase | $ 1,077,380,000 | $ 245,439,000 | $ 2,272,222,000 | $ 1,328,898,000 | ||||
Stock repurchase program | ||||||||
Equity, Class of Treasury Stock [Line Items] | ||||||||
Board authorized increase | $ 5,000,000,000 | |||||||
Total Number of Shares Repurchased (in shares) | 1,474 | 1,789 | 1,344 | |||||
Total Cost of Repurchase | $ 925,099,000 | $ 724,485,000 | $ 461,998,000 | |||||
Average Price Paid Per Share (in dollars per share) | $ 519.30 | $ 404.98 | $ 343.73 | |||||
Amount Available Under Repurchase Program | $ 6,311,429,000 | $ 4,661,845,000 | $ 5,586,944,000 | $ 1,311,429,000 | $ 4,661,845,000 | $ 1,773,427,000 |
ACCUMULATED OTHER COMPREHENSI_3
ACCUMULATED OTHER COMPREHENSIVE LOSS - Components of Accumulated Other Comprehensive Loss (Details) $ in Thousands | 9 Months Ended | |
Mar. 28, 2021USD ($) | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | $ 5,172,494 | [1] |
Other comprehensive income (loss) before reclassifications | 29,344 | |
Losses reclassified from accumulated other comprehensive loss to net income | 1,570 | |
Net current-period other comprehensive income (loss) | 30,914 | |
Ending balance | 5,371,616 | |
Accumulated Foreign Currency Translation Adjustment | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | (45,811) | |
Other comprehensive income (loss) before reclassifications | 20,231 | |
Losses reclassified from accumulated other comprehensive loss to net income | 0 | |
Net current-period other comprehensive income (loss) | 20,231 | |
Ending balance | (25,580) | |
Accumulated Unrealized Gain or Loss on Cash flow hedges | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | (32,796) | |
Other comprehensive income (loss) before reclassifications | 12,546 | |
Losses reclassified from accumulated other comprehensive loss to net income | 843 | |
Net current-period other comprehensive income (loss) | 13,389 | |
Ending balance | (19,407) | |
Accumulated Unrealized Holding Gain or Loss on Available-For-Sale Investments | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | 4,923 | |
Other comprehensive income (loss) before reclassifications | (3,667) | |
Losses reclassified from accumulated other comprehensive loss to net income | 727 | |
Net current-period other comprehensive income (loss) | (2,940) | |
Ending balance | 1,983 | |
Accumulated Unrealized Components of Defined Benefit Plans | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | (20,527) | |
Other comprehensive income (loss) before reclassifications | 234 | |
Losses reclassified from accumulated other comprehensive loss to net income | 0 | |
Net current-period other comprehensive income (loss) | 234 | |
Ending balance | (20,293) | |
Total | ||
Change in Accumulated Other Comprehensive Loss | ||
Beginning balance | (94,211) | |
Ending balance | $ (63,297) | |
[1] | Derived from audited financial statements |
Uncategorized Items - lrcx-2021
Label | Element | Value |
Restricted Cash and Cash Equivalents | us-gaap_RestrictedCashAndCashEquivalents | $ 254,155,000 |
Restricted Cash and Cash Equivalents | us-gaap_RestrictedCashAndCashEquivalents | 253,460,000 |
Dividends Payable | us-gaap_DividendsPayableCurrentAndNoncurrent | 167,740,000 |
Dividends Payable | us-gaap_DividendsPayableCurrentAndNoncurrent | $ 185,390,000 |